1
|
Weber JS, Carlino MS, Khattak A, Meniawy T, Ansstas G, Taylor MH, Kim KB, McKean M, Long GV, Sullivan RJ, Faries M, Tran TT, Cowey CL, Pecora A, Shaheen M, Segar J, Medina T, Atkinson V, Gibney GT, Luke JJ, Thomas S, Buchbinder EI, Healy JA, Huang M, Morrissey M, Feldman I, Sehgal V, Robert-Tissot C, Hou P, Zhu L, Brown M, Aanur P, Meehan RS, Zaks T. Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study. Lancet 2024; 403:632-644. [PMID: 38246194 DOI: 10.1016/s0140-6736(23)02268-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/09/2023] [Revised: 09/22/2023] [Accepted: 10/06/2023] [Indexed: 01/23/2024]
Abstract
BACKGROUND Checkpoint inhibitors are standard adjuvant treatment for stage IIB-IV resected melanoma, but many patients recur. Our study aimed to evaluate whether mRNA-4157 (V940), a novel mRNA-based individualised neoantigen therapy, combined with pembrolizumab, improved recurrence-free survival and distant metastasis-free survival versus pembrolizumab monotherapy in resected high-risk melanoma. METHODS We did an open-label, randomised, phase 2b, adjuvant study of mRNA-4157 plus pembrolizumab versus pembrolizumab monotherapy in patients, enrolled from sites in the USA and Australia, with completely resected high-risk cutaneous melanoma. Patients with completely resected melanoma (stage IIIB-IV) were assigned 2:1 to receive open-label mRNA-4157 plus pembrolizumab or pembrolizumab monotherapy. mRNA-4157 was administered intramuscularly (maximum nine doses) and pembrolizumab intravenously (maximum 18 doses) in 3-week cycles. The primary endpoint was recurrence-free survival in the intention-to-treat population. This ongoing trial is registered at ClinicalTrials.gov, NCT03897881. FINDINGS From July 18, 2019, to Sept 30, 2021, 157 patients were assigned to mRNA-4157 plus pembrolizumab combination therapy (n=107) or pembrolizumab monotherapy (n=50); median follow-up was 23 months and 24 months, respectively. Recurrence-free survival was longer with combination versus monotherapy (hazard ratio [HR] for recurrence or death, 0·561 [95% CI 0·309-1·017]; two-sided p=0·053), with lower recurrence or death event rate (24 [22%] of 107 vs 20 [40%] of 50); 18-month recurrence-free survival was 79% (95% CI 69·0-85·6) versus 62% (46·9-74·3). Most treatment-related adverse events were grade 1-2. Grade ≥3 treatment-related adverse events occurred in 25% of patients in the combination group and 18% of patients in the monotherapy group, with no mRNA-4157-related grade 4-5 events. Immune-mediated adverse event frequency was similar for the combination (37 [36%]) and monotherapy (18 [36%]) groups. INTERPRETATION Adjuvant mRNA-4157 plus pembrolizumab prolonged recurrence-free survival versus pembrolizumab monotherapy in patients with resected high-risk melanoma and showed a manageable safety profile. These results provide evidence that an mRNA-based individualised neoantigen therapy might be beneficial in the adjuvant setting. FUNDING Moderna in collaboration with Merck Sharp & Dohme, a subsidiary of Merck & Co, Rahway, NJ, USA.
Collapse
Affiliation(s)
- Jeffrey S Weber
- Laura and Isaac Perlmutter Cancer Center at NYU Langone Health, New York, NY, USA.
| | - Matteo S Carlino
- Westmead and Blacktown Hospitals, Melanoma Institute Australia, Sydney, NSW, Australia
| | - Adnan Khattak
- Hollywood Private Hospital, Perth, WA, Australia; Edith Cowan University, Perth, WA, Australia
| | - Tarek Meniawy
- Saint John of God Subiaco Hospital, Subiaco, WA, Australia
| | - George Ansstas
- Washington University School of Medicine, St Louis, MO, USA
| | - Matthew H Taylor
- Earle A Chiles Research Institute, Providence Cancer Institute, Portland, OR, USA
| | - Kevin B Kim
- California Pacific Medical Center Research Institute, San Francisco, CA, USA
| | - Meredith McKean
- Sarah Cannon Research Institute at Tennessee Oncology, Nashville, TN, USA
| | - Georgina V Long
- Melanoma Institute Australia, The University of Sydney, Sydney, NSW, Australia; Royal North Shore and Mater Hospitals, Sydney, NSW, Australia
| | - Ryan J Sullivan
- Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA
| | - Mark Faries
- The Angeles Clinic and Research Institute, a Cedars-Sinai affiliate, Los Angeles, CA, USA
| | - Thuy T Tran
- Smilow Cancer Center at Yale New Haven Hospital, New Haven, CT, USA
| | | | - Andrew Pecora
- Hackensack University Medical Center, Hackensack, NJ, USA
| | - Montaser Shaheen
- The University of Texas Health Science Center at San Antonio, San Antonio, TX, USA
| | | | | | | | - Geoffrey T Gibney
- Georgetown-Lombardi Comprehensive Cancer Center, Washington, DC, USA
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
2
|
Minnogue V, Morrissey M, Matvienko-Sikar K, Gorman G, Terres A, Hayes CB. Usability and applicability of research knowledge translation models in a national health service. Eur J Public Health 2021. [DOI: 10.1093/eurpub/ckab165.449] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Abstract
Background
The Health Service Executive in Ireland aims to facilitate the translation of research and innovation into policy and practice and increase dissemination of research. Previous HSE surveys showed that a high volume of research was undertaken but the impact on practice and policy was unclear. Researchers reported sharing their research in publications, conferences, and through education and training but identified problems in engaging with practice and policy stakeholders. Survey respondents requested help with dissemination and getting research into practice. An organisation-wide project to identify frameworks to support knowledge translation (KT), dissemination, and impact identified a recommended methodology, created guidance, and training for knowledge creators and users.
Objectives
Provide a series of six guides, tools and templates, to support knowledge creators and users across the organisation Provide online training to support translation and dissemination of research knowledge Underline the importance of planning KT and impact at research commencement and identify the planned outcomes Develop user-friendly training to explain the elements of KT and dissemination.
Results
Two pilot studies were undertaken to test the guidance which, although positively received, resulted in changes to the format, design, and language to increase useability. An explainer video and six online training modules were developed, based on the guidance and pilot feedback to be rolled out from July 2021. Learning was enhanced through transfer of complex information and models into short training modules to be accessed by researchers with a range of experience and understanding.
Conclusions
KT is a complex area and developing education and training for it requires understanding the different learning needs of knowledge creators and users. Education and training should focus on the need for KT and impact from the start of a project.
Key messages
Practical guidance to assist researchers in translation of their research findings into practice and improving dissemination enhances service user impact. Education and training should focus on the need to plan for KT from the start of a project.
Collapse
Affiliation(s)
- V Minnogue
- Research and Evidence, Health Service Executive, Dublin, Ireland
| | - M Morrissey
- Research and Evidence, Health Service Executive, Dublin, Ireland
| | | | - G Gorman
- School of Public Health, University College Cork, Cork, Ireland
| | - A Terres
- Research and Evidence, Health Service Executive, Dublin, Ireland
| | - CB Hayes
- School of Medicine, Trinity College Dublin, Dublin, Ireland
- Research and Evidence, Health Service Executive, Dublin, Ireland
| |
Collapse
|
3
|
Morrissey M. ROLE OF POLICY AND POLICY ADVOCACY IN PALLIATIVE AND END-OF-LIFE CARE FOR LGBTQ PERSONS. Innov Aging 2018. [DOI: 10.1093/geroni/igy023.1262] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Affiliation(s)
- M Morrissey
- Fordham University, White Plains, New York, United States
| |
Collapse
|
4
|
Morrissey M, Byrne R, Lynam-Lennon N, Butler C, Nulty C, Kennedy S, Dunne M, McCabe N, Reynolds J, O’Sullivan J. PO-388 The gastrointestinal tract tumour microenvironment differentially influences maturation of and cytokine secretion from dendritic cells. ESMO Open 2018. [DOI: 10.1136/esmoopen-2018-eacr25.894] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022] Open
|
5
|
Olopade OI, Pitt JJ, Riester M, Odetunde A, Yoshimatsu T, Labrot E, Ademola A, Sanni A, Okedere B, Mahan S, Nwosu I, Leary R, Ajani M, Johnson RS, Sveen E, Zheng Y, Wang S, Fitzgerald DJ, Grundstad J, Tuteja J, Clayton W, Khramtsova G, Oludara M, Omodele F, Benson O, Adeoye A, Morhason-Bello O, Ogundiran T, Babalola C, Popoola A, Morrissey M, Chen L, Huo D, Falusi A, Winckler W, Obafunwa J, Papoutsakis D, Ojengbede O, White KP, Ibrahim N, Oluwasola O, Barretina J. Abstract PD8-05: Comparative analysis of the genomic landscape of breast cancers from women of African and European ancestry. Cancer Res 2017. [DOI: 10.1158/1538-7445.sabcs16-pd8-05] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Objectives: Paucity of data on populations of African Ancestry in clinical trials continues to limit our ability to design and implement innovative solutions to narrow the breast cancer survival gap amongst Africans, African Americans, and European Americans. We have developed a cross-continent research infrastructure to examine the spectrum of genomic alterations in breast tumors from West Africa and subsequently, to compare them to tumors from African American women and women of European Ancestry in The Cancer Genome Atlas (TCGA) database.
Methods: Consecutive women with breast cancer presenting for treatment at the University College Hospital, Ibadan and at Lagos State University Teaching Hospital, Lagos, Nigeria gave informed consent and were recruited to the West African Breast Cancer Study (WABCS) between 2013-2016. Tumor-normal pairs were subjected to exome and/or high-depth (90x) genome sequencing. High confidence somatic mutations (substitutions, insertions/deletions and structural variants) were obtained by using multiple variant callers. Furthermore, 1,089 exomic and 80 genomic breast tumor-normal pairs from TCGA were harmonized with WABCS samples, resulting in a cohort of 147 West Africans (147 exome; 40 genome), 154 African Americans (154 exome; 31 genome), and 776 Caucasians (776 exome; 43 genome).
Results: Across the exomes, genes commonly altered in breast cancer in TCGA are also altered in women of African ancestry, but the mutational spectrum is quite different, demonstrating overrepresentation of tumors with aggressive phenotypes. Overall, TP53 (65%), ERBB2 (27%), and GATA3 (17%) showed statistically significant higher alteration frequencies in West Africans and African Americans. In contrast, PIK3CA (24%) was less frequently mutated. Of note, GATA3 mutation was statistically significantly more frequent in Nigerians (39%) and African Americans (16.7%) compared to Caucasians (10.5%), in ER-positive cancers. Analysis on Structural Variants (SV), on the other hand, has shown that the genome-wide SV counts among three populations are comparable in ER-negative cancers, while Nigerians have significantly more SV counts compared to African Americans (P=0.0013) or European Americans (P=2.9x10-5) in ER-positive cancers. Similarly, genome-wide substitution patterns in ER+ and ER- cancers varied widely by race/ethnicity. In ER- cases, West Africans carried the highest proportion of canonical APOBEC-associated substitutions, particularly C>T transitions. Conversely, European Americans with ER+ disease showed a higher proportion of C>T than both West Africans (Welch t-test P = 0.044) and African Americans (Welch t-test P = 0.011). Mutation signature analyses highlighted multiple APOBEC signatures, with notable contribution differences across ancestry and ER status. A signature likely corresponding to DNA damage repair correlated with the proportion of genetic ancestry, being most prevalent in European Americans and least common in Nigerians, particularly in ER-negative cancers, with African Americans showing a degree of this signature's contribution in between the two populations (linear model adjusted for age, P=1.0x10-10).
Conclusions: Overall, our data suggests mutation spectra differences in across race/ethnicity and geography. Identification of molecular characteristics such as higher rates of HER2 enriched tumors and higher rates of GATA3 mutations in ER positive tumors are beginning to reveal the genomic basis of race-associated phenotypes and outcomes in breast cancer. Population differences in frequency and spectrum of mutations should now inform the design of innovative clinical trials that improve health equity and accelerate Precision Oncology care in diverse populations.
Citation Format: Olopade OI, Pitt JJ, Riester M, Odetunde A, Yoshimatsu T, Labrot E, Ademola A, Sanni A, Okedere B, Mahan S, Nwosu I, Leary R, Ajani M, Johnson RS, Sveen E, Zheng Y, Wang S, Fitzgerald DJ, Grundstad J, Tuteja J, Clayton W, Khramtsova G, Oludara M, Omodele F, Benson O, Adeoye A, Morhason-Bello O, Ogundiran T, Babalola C, Popoola A, Morrissey M, Chen L, Huo D, Falusi A, Winckler W, Obafunwa J, Papoutsakis D, Ojengbede O, White KP, Ibrahim N, Oluwasola O, Barretina J. Comparative analysis of the genomic landscape of breast cancers from women of African and European ancestry [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr PD8-05.
Collapse
Affiliation(s)
- OI Olopade
- Center for Global Health, The University of Chicago, Chicago, IL; Institute for Genomics and Systems Biology, The University of Chicago, Chicago, IL; Novartis Institutes for BioMedical Research, Cambridge, MA; Institute for Advanced Medical Research and Training, College of Medicine, University of Ibadan, Ibadan, Oyo, Nigeria; University of Ibadan, Ibadan, Oyo, Nigeria; Lagos State University Teaching Hospital, Ikeja, Lagos, Nigeria; Oncology Unit, Lagos State University, Ikeja, Lagos, Nigeria; The University of Chicago, Chicago, IL, Nigeria; Centre for Population & Reproductive Health, College of Medicine, University of Ibadan, Ibadan, Oyo, Nigeria
| | - JJ Pitt
- Center for Global Health, The University of Chicago, Chicago, IL; Institute for Genomics and Systems Biology, The University of Chicago, Chicago, IL; Novartis Institutes for BioMedical Research, Cambridge, MA; Institute for Advanced Medical Research and Training, College of Medicine, University of Ibadan, Ibadan, Oyo, Nigeria; University of Ibadan, Ibadan, Oyo, Nigeria; Lagos State University Teaching Hospital, Ikeja, Lagos, Nigeria; Oncology Unit, Lagos State University, Ikeja, Lagos, Nigeria; The University of Chicago, Chicago, IL, Nigeria; Centre for Population & Reproductive Health, College of Medicine, University of Ibadan, Ibadan, Oyo, Nigeria
| | - M Riester
- Center for Global Health, The University of Chicago, Chicago, IL; Institute for Genomics and Systems Biology, The University of Chicago, Chicago, IL; Novartis Institutes for BioMedical Research, Cambridge, MA; Institute for Advanced Medical Research and Training, College of Medicine, University of Ibadan, Ibadan, Oyo, Nigeria; University of Ibadan, Ibadan, Oyo, Nigeria; Lagos State University Teaching Hospital, Ikeja, Lagos, Nigeria; Oncology Unit, Lagos State University, Ikeja, Lagos, Nigeria; The University of Chicago, Chicago, IL, Nigeria; Centre for Population & Reproductive Health, College of Medicine, University of Ibadan, Ibadan, Oyo, Nigeria
| | - A Odetunde
- Center for Global Health, The University of Chicago, Chicago, IL; Institute for Genomics and Systems Biology, The University of Chicago, Chicago, IL; Novartis Institutes for BioMedical Research, Cambridge, MA; Institute for Advanced Medical Research and Training, College of Medicine, University of Ibadan, Ibadan, Oyo, Nigeria; University of Ibadan, Ibadan, Oyo, Nigeria; Lagos State University Teaching Hospital, Ikeja, Lagos, Nigeria; Oncology Unit, Lagos State University, Ikeja, Lagos, Nigeria; The University of Chicago, Chicago, IL, Nigeria; Centre for Population & Reproductive Health, College of Medicine, University of Ibadan, Ibadan, Oyo, Nigeria
| | - T Yoshimatsu
- Center for Global Health, The University of Chicago, Chicago, IL; Institute for Genomics and Systems Biology, The University of Chicago, Chicago, IL; Novartis Institutes for BioMedical Research, Cambridge, MA; Institute for Advanced Medical Research and Training, College of Medicine, University of Ibadan, Ibadan, Oyo, Nigeria; University of Ibadan, Ibadan, Oyo, Nigeria; Lagos State University Teaching Hospital, Ikeja, Lagos, Nigeria; Oncology Unit, Lagos State University, Ikeja, Lagos, Nigeria; The University of Chicago, Chicago, IL, Nigeria; Centre for Population & Reproductive Health, College of Medicine, University of Ibadan, Ibadan, Oyo, Nigeria
| | - E Labrot
- Center for Global Health, The University of Chicago, Chicago, IL; Institute for Genomics and Systems Biology, The University of Chicago, Chicago, IL; Novartis Institutes for BioMedical Research, Cambridge, MA; Institute for Advanced Medical Research and Training, College of Medicine, University of Ibadan, Ibadan, Oyo, Nigeria; University of Ibadan, Ibadan, Oyo, Nigeria; Lagos State University Teaching Hospital, Ikeja, Lagos, Nigeria; Oncology Unit, Lagos State University, Ikeja, Lagos, Nigeria; The University of Chicago, Chicago, IL, Nigeria; Centre for Population & Reproductive Health, College of Medicine, University of Ibadan, Ibadan, Oyo, Nigeria
| | - A Ademola
- Center for Global Health, The University of Chicago, Chicago, IL; Institute for Genomics and Systems Biology, The University of Chicago, Chicago, IL; Novartis Institutes for BioMedical Research, Cambridge, MA; Institute for Advanced Medical Research and Training, College of Medicine, University of Ibadan, Ibadan, Oyo, Nigeria; University of Ibadan, Ibadan, Oyo, Nigeria; Lagos State University Teaching Hospital, Ikeja, Lagos, Nigeria; Oncology Unit, Lagos State University, Ikeja, Lagos, Nigeria; The University of Chicago, Chicago, IL, Nigeria; Centre for Population & Reproductive Health, College of Medicine, University of Ibadan, Ibadan, Oyo, Nigeria
| | - A Sanni
- Center for Global Health, The University of Chicago, Chicago, IL; Institute for Genomics and Systems Biology, The University of Chicago, Chicago, IL; Novartis Institutes for BioMedical Research, Cambridge, MA; Institute for Advanced Medical Research and Training, College of Medicine, University of Ibadan, Ibadan, Oyo, Nigeria; University of Ibadan, Ibadan, Oyo, Nigeria; Lagos State University Teaching Hospital, Ikeja, Lagos, Nigeria; Oncology Unit, Lagos State University, Ikeja, Lagos, Nigeria; The University of Chicago, Chicago, IL, Nigeria; Centre for Population & Reproductive Health, College of Medicine, University of Ibadan, Ibadan, Oyo, Nigeria
| | - B Okedere
- Center for Global Health, The University of Chicago, Chicago, IL; Institute for Genomics and Systems Biology, The University of Chicago, Chicago, IL; Novartis Institutes for BioMedical Research, Cambridge, MA; Institute for Advanced Medical Research and Training, College of Medicine, University of Ibadan, Ibadan, Oyo, Nigeria; University of Ibadan, Ibadan, Oyo, Nigeria; Lagos State University Teaching Hospital, Ikeja, Lagos, Nigeria; Oncology Unit, Lagos State University, Ikeja, Lagos, Nigeria; The University of Chicago, Chicago, IL, Nigeria; Centre for Population & Reproductive Health, College of Medicine, University of Ibadan, Ibadan, Oyo, Nigeria
| | - S Mahan
- Center for Global Health, The University of Chicago, Chicago, IL; Institute for Genomics and Systems Biology, The University of Chicago, Chicago, IL; Novartis Institutes for BioMedical Research, Cambridge, MA; Institute for Advanced Medical Research and Training, College of Medicine, University of Ibadan, Ibadan, Oyo, Nigeria; University of Ibadan, Ibadan, Oyo, Nigeria; Lagos State University Teaching Hospital, Ikeja, Lagos, Nigeria; Oncology Unit, Lagos State University, Ikeja, Lagos, Nigeria; The University of Chicago, Chicago, IL, Nigeria; Centre for Population & Reproductive Health, College of Medicine, University of Ibadan, Ibadan, Oyo, Nigeria
| | - I Nwosu
- Center for Global Health, The University of Chicago, Chicago, IL; Institute for Genomics and Systems Biology, The University of Chicago, Chicago, IL; Novartis Institutes for BioMedical Research, Cambridge, MA; Institute for Advanced Medical Research and Training, College of Medicine, University of Ibadan, Ibadan, Oyo, Nigeria; University of Ibadan, Ibadan, Oyo, Nigeria; Lagos State University Teaching Hospital, Ikeja, Lagos, Nigeria; Oncology Unit, Lagos State University, Ikeja, Lagos, Nigeria; The University of Chicago, Chicago, IL, Nigeria; Centre for Population & Reproductive Health, College of Medicine, University of Ibadan, Ibadan, Oyo, Nigeria
| | - R Leary
- Center for Global Health, The University of Chicago, Chicago, IL; Institute for Genomics and Systems Biology, The University of Chicago, Chicago, IL; Novartis Institutes for BioMedical Research, Cambridge, MA; Institute for Advanced Medical Research and Training, College of Medicine, University of Ibadan, Ibadan, Oyo, Nigeria; University of Ibadan, Ibadan, Oyo, Nigeria; Lagos State University Teaching Hospital, Ikeja, Lagos, Nigeria; Oncology Unit, Lagos State University, Ikeja, Lagos, Nigeria; The University of Chicago, Chicago, IL, Nigeria; Centre for Population & Reproductive Health, College of Medicine, University of Ibadan, Ibadan, Oyo, Nigeria
| | - M Ajani
- Center for Global Health, The University of Chicago, Chicago, IL; Institute for Genomics and Systems Biology, The University of Chicago, Chicago, IL; Novartis Institutes for BioMedical Research, Cambridge, MA; Institute for Advanced Medical Research and Training, College of Medicine, University of Ibadan, Ibadan, Oyo, Nigeria; University of Ibadan, Ibadan, Oyo, Nigeria; Lagos State University Teaching Hospital, Ikeja, Lagos, Nigeria; Oncology Unit, Lagos State University, Ikeja, Lagos, Nigeria; The University of Chicago, Chicago, IL, Nigeria; Centre for Population & Reproductive Health, College of Medicine, University of Ibadan, Ibadan, Oyo, Nigeria
| | - RS Johnson
- Center for Global Health, The University of Chicago, Chicago, IL; Institute for Genomics and Systems Biology, The University of Chicago, Chicago, IL; Novartis Institutes for BioMedical Research, Cambridge, MA; Institute for Advanced Medical Research and Training, College of Medicine, University of Ibadan, Ibadan, Oyo, Nigeria; University of Ibadan, Ibadan, Oyo, Nigeria; Lagos State University Teaching Hospital, Ikeja, Lagos, Nigeria; Oncology Unit, Lagos State University, Ikeja, Lagos, Nigeria; The University of Chicago, Chicago, IL, Nigeria; Centre for Population & Reproductive Health, College of Medicine, University of Ibadan, Ibadan, Oyo, Nigeria
| | - E Sveen
- Center for Global Health, The University of Chicago, Chicago, IL; Institute for Genomics and Systems Biology, The University of Chicago, Chicago, IL; Novartis Institutes for BioMedical Research, Cambridge, MA; Institute for Advanced Medical Research and Training, College of Medicine, University of Ibadan, Ibadan, Oyo, Nigeria; University of Ibadan, Ibadan, Oyo, Nigeria; Lagos State University Teaching Hospital, Ikeja, Lagos, Nigeria; Oncology Unit, Lagos State University, Ikeja, Lagos, Nigeria; The University of Chicago, Chicago, IL, Nigeria; Centre for Population & Reproductive Health, College of Medicine, University of Ibadan, Ibadan, Oyo, Nigeria
| | - Y Zheng
- Center for Global Health, The University of Chicago, Chicago, IL; Institute for Genomics and Systems Biology, The University of Chicago, Chicago, IL; Novartis Institutes for BioMedical Research, Cambridge, MA; Institute for Advanced Medical Research and Training, College of Medicine, University of Ibadan, Ibadan, Oyo, Nigeria; University of Ibadan, Ibadan, Oyo, Nigeria; Lagos State University Teaching Hospital, Ikeja, Lagos, Nigeria; Oncology Unit, Lagos State University, Ikeja, Lagos, Nigeria; The University of Chicago, Chicago, IL, Nigeria; Centre for Population & Reproductive Health, College of Medicine, University of Ibadan, Ibadan, Oyo, Nigeria
| | - S Wang
- Center for Global Health, The University of Chicago, Chicago, IL; Institute for Genomics and Systems Biology, The University of Chicago, Chicago, IL; Novartis Institutes for BioMedical Research, Cambridge, MA; Institute for Advanced Medical Research and Training, College of Medicine, University of Ibadan, Ibadan, Oyo, Nigeria; University of Ibadan, Ibadan, Oyo, Nigeria; Lagos State University Teaching Hospital, Ikeja, Lagos, Nigeria; Oncology Unit, Lagos State University, Ikeja, Lagos, Nigeria; The University of Chicago, Chicago, IL, Nigeria; Centre for Population & Reproductive Health, College of Medicine, University of Ibadan, Ibadan, Oyo, Nigeria
| | - DJ Fitzgerald
- Center for Global Health, The University of Chicago, Chicago, IL; Institute for Genomics and Systems Biology, The University of Chicago, Chicago, IL; Novartis Institutes for BioMedical Research, Cambridge, MA; Institute for Advanced Medical Research and Training, College of Medicine, University of Ibadan, Ibadan, Oyo, Nigeria; University of Ibadan, Ibadan, Oyo, Nigeria; Lagos State University Teaching Hospital, Ikeja, Lagos, Nigeria; Oncology Unit, Lagos State University, Ikeja, Lagos, Nigeria; The University of Chicago, Chicago, IL, Nigeria; Centre for Population & Reproductive Health, College of Medicine, University of Ibadan, Ibadan, Oyo, Nigeria
| | - J Grundstad
- Center for Global Health, The University of Chicago, Chicago, IL; Institute for Genomics and Systems Biology, The University of Chicago, Chicago, IL; Novartis Institutes for BioMedical Research, Cambridge, MA; Institute for Advanced Medical Research and Training, College of Medicine, University of Ibadan, Ibadan, Oyo, Nigeria; University of Ibadan, Ibadan, Oyo, Nigeria; Lagos State University Teaching Hospital, Ikeja, Lagos, Nigeria; Oncology Unit, Lagos State University, Ikeja, Lagos, Nigeria; The University of Chicago, Chicago, IL, Nigeria; Centre for Population & Reproductive Health, College of Medicine, University of Ibadan, Ibadan, Oyo, Nigeria
| | - J Tuteja
- Center for Global Health, The University of Chicago, Chicago, IL; Institute for Genomics and Systems Biology, The University of Chicago, Chicago, IL; Novartis Institutes for BioMedical Research, Cambridge, MA; Institute for Advanced Medical Research and Training, College of Medicine, University of Ibadan, Ibadan, Oyo, Nigeria; University of Ibadan, Ibadan, Oyo, Nigeria; Lagos State University Teaching Hospital, Ikeja, Lagos, Nigeria; Oncology Unit, Lagos State University, Ikeja, Lagos, Nigeria; The University of Chicago, Chicago, IL, Nigeria; Centre for Population & Reproductive Health, College of Medicine, University of Ibadan, Ibadan, Oyo, Nigeria
| | - W Clayton
- Center for Global Health, The University of Chicago, Chicago, IL; Institute for Genomics and Systems Biology, The University of Chicago, Chicago, IL; Novartis Institutes for BioMedical Research, Cambridge, MA; Institute for Advanced Medical Research and Training, College of Medicine, University of Ibadan, Ibadan, Oyo, Nigeria; University of Ibadan, Ibadan, Oyo, Nigeria; Lagos State University Teaching Hospital, Ikeja, Lagos, Nigeria; Oncology Unit, Lagos State University, Ikeja, Lagos, Nigeria; The University of Chicago, Chicago, IL, Nigeria; Centre for Population & Reproductive Health, College of Medicine, University of Ibadan, Ibadan, Oyo, Nigeria
| | - G Khramtsova
- Center for Global Health, The University of Chicago, Chicago, IL; Institute for Genomics and Systems Biology, The University of Chicago, Chicago, IL; Novartis Institutes for BioMedical Research, Cambridge, MA; Institute for Advanced Medical Research and Training, College of Medicine, University of Ibadan, Ibadan, Oyo, Nigeria; University of Ibadan, Ibadan, Oyo, Nigeria; Lagos State University Teaching Hospital, Ikeja, Lagos, Nigeria; Oncology Unit, Lagos State University, Ikeja, Lagos, Nigeria; The University of Chicago, Chicago, IL, Nigeria; Centre for Population & Reproductive Health, College of Medicine, University of Ibadan, Ibadan, Oyo, Nigeria
| | - M Oludara
- Center for Global Health, The University of Chicago, Chicago, IL; Institute for Genomics and Systems Biology, The University of Chicago, Chicago, IL; Novartis Institutes for BioMedical Research, Cambridge, MA; Institute for Advanced Medical Research and Training, College of Medicine, University of Ibadan, Ibadan, Oyo, Nigeria; University of Ibadan, Ibadan, Oyo, Nigeria; Lagos State University Teaching Hospital, Ikeja, Lagos, Nigeria; Oncology Unit, Lagos State University, Ikeja, Lagos, Nigeria; The University of Chicago, Chicago, IL, Nigeria; Centre for Population & Reproductive Health, College of Medicine, University of Ibadan, Ibadan, Oyo, Nigeria
| | - F Omodele
- Center for Global Health, The University of Chicago, Chicago, IL; Institute for Genomics and Systems Biology, The University of Chicago, Chicago, IL; Novartis Institutes for BioMedical Research, Cambridge, MA; Institute for Advanced Medical Research and Training, College of Medicine, University of Ibadan, Ibadan, Oyo, Nigeria; University of Ibadan, Ibadan, Oyo, Nigeria; Lagos State University Teaching Hospital, Ikeja, Lagos, Nigeria; Oncology Unit, Lagos State University, Ikeja, Lagos, Nigeria; The University of Chicago, Chicago, IL, Nigeria; Centre for Population & Reproductive Health, College of Medicine, University of Ibadan, Ibadan, Oyo, Nigeria
| | - O Benson
- Center for Global Health, The University of Chicago, Chicago, IL; Institute for Genomics and Systems Biology, The University of Chicago, Chicago, IL; Novartis Institutes for BioMedical Research, Cambridge, MA; Institute for Advanced Medical Research and Training, College of Medicine, University of Ibadan, Ibadan, Oyo, Nigeria; University of Ibadan, Ibadan, Oyo, Nigeria; Lagos State University Teaching Hospital, Ikeja, Lagos, Nigeria; Oncology Unit, Lagos State University, Ikeja, Lagos, Nigeria; The University of Chicago, Chicago, IL, Nigeria; Centre for Population & Reproductive Health, College of Medicine, University of Ibadan, Ibadan, Oyo, Nigeria
| | - A Adeoye
- Center for Global Health, The University of Chicago, Chicago, IL; Institute for Genomics and Systems Biology, The University of Chicago, Chicago, IL; Novartis Institutes for BioMedical Research, Cambridge, MA; Institute for Advanced Medical Research and Training, College of Medicine, University of Ibadan, Ibadan, Oyo, Nigeria; University of Ibadan, Ibadan, Oyo, Nigeria; Lagos State University Teaching Hospital, Ikeja, Lagos, Nigeria; Oncology Unit, Lagos State University, Ikeja, Lagos, Nigeria; The University of Chicago, Chicago, IL, Nigeria; Centre for Population & Reproductive Health, College of Medicine, University of Ibadan, Ibadan, Oyo, Nigeria
| | - O Morhason-Bello
- Center for Global Health, The University of Chicago, Chicago, IL; Institute for Genomics and Systems Biology, The University of Chicago, Chicago, IL; Novartis Institutes for BioMedical Research, Cambridge, MA; Institute for Advanced Medical Research and Training, College of Medicine, University of Ibadan, Ibadan, Oyo, Nigeria; University of Ibadan, Ibadan, Oyo, Nigeria; Lagos State University Teaching Hospital, Ikeja, Lagos, Nigeria; Oncology Unit, Lagos State University, Ikeja, Lagos, Nigeria; The University of Chicago, Chicago, IL, Nigeria; Centre for Population & Reproductive Health, College of Medicine, University of Ibadan, Ibadan, Oyo, Nigeria
| | - T Ogundiran
- Center for Global Health, The University of Chicago, Chicago, IL; Institute for Genomics and Systems Biology, The University of Chicago, Chicago, IL; Novartis Institutes for BioMedical Research, Cambridge, MA; Institute for Advanced Medical Research and Training, College of Medicine, University of Ibadan, Ibadan, Oyo, Nigeria; University of Ibadan, Ibadan, Oyo, Nigeria; Lagos State University Teaching Hospital, Ikeja, Lagos, Nigeria; Oncology Unit, Lagos State University, Ikeja, Lagos, Nigeria; The University of Chicago, Chicago, IL, Nigeria; Centre for Population & Reproductive Health, College of Medicine, University of Ibadan, Ibadan, Oyo, Nigeria
| | - C Babalola
- Center for Global Health, The University of Chicago, Chicago, IL; Institute for Genomics and Systems Biology, The University of Chicago, Chicago, IL; Novartis Institutes for BioMedical Research, Cambridge, MA; Institute for Advanced Medical Research and Training, College of Medicine, University of Ibadan, Ibadan, Oyo, Nigeria; University of Ibadan, Ibadan, Oyo, Nigeria; Lagos State University Teaching Hospital, Ikeja, Lagos, Nigeria; Oncology Unit, Lagos State University, Ikeja, Lagos, Nigeria; The University of Chicago, Chicago, IL, Nigeria; Centre for Population & Reproductive Health, College of Medicine, University of Ibadan, Ibadan, Oyo, Nigeria
| | - A Popoola
- Center for Global Health, The University of Chicago, Chicago, IL; Institute for Genomics and Systems Biology, The University of Chicago, Chicago, IL; Novartis Institutes for BioMedical Research, Cambridge, MA; Institute for Advanced Medical Research and Training, College of Medicine, University of Ibadan, Ibadan, Oyo, Nigeria; University of Ibadan, Ibadan, Oyo, Nigeria; Lagos State University Teaching Hospital, Ikeja, Lagos, Nigeria; Oncology Unit, Lagos State University, Ikeja, Lagos, Nigeria; The University of Chicago, Chicago, IL, Nigeria; Centre for Population & Reproductive Health, College of Medicine, University of Ibadan, Ibadan, Oyo, Nigeria
| | - M Morrissey
- Center for Global Health, The University of Chicago, Chicago, IL; Institute for Genomics and Systems Biology, The University of Chicago, Chicago, IL; Novartis Institutes for BioMedical Research, Cambridge, MA; Institute for Advanced Medical Research and Training, College of Medicine, University of Ibadan, Ibadan, Oyo, Nigeria; University of Ibadan, Ibadan, Oyo, Nigeria; Lagos State University Teaching Hospital, Ikeja, Lagos, Nigeria; Oncology Unit, Lagos State University, Ikeja, Lagos, Nigeria; The University of Chicago, Chicago, IL, Nigeria; Centre for Population & Reproductive Health, College of Medicine, University of Ibadan, Ibadan, Oyo, Nigeria
| | - L Chen
- Center for Global Health, The University of Chicago, Chicago, IL; Institute for Genomics and Systems Biology, The University of Chicago, Chicago, IL; Novartis Institutes for BioMedical Research, Cambridge, MA; Institute for Advanced Medical Research and Training, College of Medicine, University of Ibadan, Ibadan, Oyo, Nigeria; University of Ibadan, Ibadan, Oyo, Nigeria; Lagos State University Teaching Hospital, Ikeja, Lagos, Nigeria; Oncology Unit, Lagos State University, Ikeja, Lagos, Nigeria; The University of Chicago, Chicago, IL, Nigeria; Centre for Population & Reproductive Health, College of Medicine, University of Ibadan, Ibadan, Oyo, Nigeria
| | - D Huo
- Center for Global Health, The University of Chicago, Chicago, IL; Institute for Genomics and Systems Biology, The University of Chicago, Chicago, IL; Novartis Institutes for BioMedical Research, Cambridge, MA; Institute for Advanced Medical Research and Training, College of Medicine, University of Ibadan, Ibadan, Oyo, Nigeria; University of Ibadan, Ibadan, Oyo, Nigeria; Lagos State University Teaching Hospital, Ikeja, Lagos, Nigeria; Oncology Unit, Lagos State University, Ikeja, Lagos, Nigeria; The University of Chicago, Chicago, IL, Nigeria; Centre for Population & Reproductive Health, College of Medicine, University of Ibadan, Ibadan, Oyo, Nigeria
| | - A Falusi
- Center for Global Health, The University of Chicago, Chicago, IL; Institute for Genomics and Systems Biology, The University of Chicago, Chicago, IL; Novartis Institutes for BioMedical Research, Cambridge, MA; Institute for Advanced Medical Research and Training, College of Medicine, University of Ibadan, Ibadan, Oyo, Nigeria; University of Ibadan, Ibadan, Oyo, Nigeria; Lagos State University Teaching Hospital, Ikeja, Lagos, Nigeria; Oncology Unit, Lagos State University, Ikeja, Lagos, Nigeria; The University of Chicago, Chicago, IL, Nigeria; Centre for Population & Reproductive Health, College of Medicine, University of Ibadan, Ibadan, Oyo, Nigeria
| | - W Winckler
- Center for Global Health, The University of Chicago, Chicago, IL; Institute for Genomics and Systems Biology, The University of Chicago, Chicago, IL; Novartis Institutes for BioMedical Research, Cambridge, MA; Institute for Advanced Medical Research and Training, College of Medicine, University of Ibadan, Ibadan, Oyo, Nigeria; University of Ibadan, Ibadan, Oyo, Nigeria; Lagos State University Teaching Hospital, Ikeja, Lagos, Nigeria; Oncology Unit, Lagos State University, Ikeja, Lagos, Nigeria; The University of Chicago, Chicago, IL, Nigeria; Centre for Population & Reproductive Health, College of Medicine, University of Ibadan, Ibadan, Oyo, Nigeria
| | - J Obafunwa
- Center for Global Health, The University of Chicago, Chicago, IL; Institute for Genomics and Systems Biology, The University of Chicago, Chicago, IL; Novartis Institutes for BioMedical Research, Cambridge, MA; Institute for Advanced Medical Research and Training, College of Medicine, University of Ibadan, Ibadan, Oyo, Nigeria; University of Ibadan, Ibadan, Oyo, Nigeria; Lagos State University Teaching Hospital, Ikeja, Lagos, Nigeria; Oncology Unit, Lagos State University, Ikeja, Lagos, Nigeria; The University of Chicago, Chicago, IL, Nigeria; Centre for Population & Reproductive Health, College of Medicine, University of Ibadan, Ibadan, Oyo, Nigeria
| | - D Papoutsakis
- Center for Global Health, The University of Chicago, Chicago, IL; Institute for Genomics and Systems Biology, The University of Chicago, Chicago, IL; Novartis Institutes for BioMedical Research, Cambridge, MA; Institute for Advanced Medical Research and Training, College of Medicine, University of Ibadan, Ibadan, Oyo, Nigeria; University of Ibadan, Ibadan, Oyo, Nigeria; Lagos State University Teaching Hospital, Ikeja, Lagos, Nigeria; Oncology Unit, Lagos State University, Ikeja, Lagos, Nigeria; The University of Chicago, Chicago, IL, Nigeria; Centre for Population & Reproductive Health, College of Medicine, University of Ibadan, Ibadan, Oyo, Nigeria
| | - O Ojengbede
- Center for Global Health, The University of Chicago, Chicago, IL; Institute for Genomics and Systems Biology, The University of Chicago, Chicago, IL; Novartis Institutes for BioMedical Research, Cambridge, MA; Institute for Advanced Medical Research and Training, College of Medicine, University of Ibadan, Ibadan, Oyo, Nigeria; University of Ibadan, Ibadan, Oyo, Nigeria; Lagos State University Teaching Hospital, Ikeja, Lagos, Nigeria; Oncology Unit, Lagos State University, Ikeja, Lagos, Nigeria; The University of Chicago, Chicago, IL, Nigeria; Centre for Population & Reproductive Health, College of Medicine, University of Ibadan, Ibadan, Oyo, Nigeria
| | - KP White
- Center for Global Health, The University of Chicago, Chicago, IL; Institute for Genomics and Systems Biology, The University of Chicago, Chicago, IL; Novartis Institutes for BioMedical Research, Cambridge, MA; Institute for Advanced Medical Research and Training, College of Medicine, University of Ibadan, Ibadan, Oyo, Nigeria; University of Ibadan, Ibadan, Oyo, Nigeria; Lagos State University Teaching Hospital, Ikeja, Lagos, Nigeria; Oncology Unit, Lagos State University, Ikeja, Lagos, Nigeria; The University of Chicago, Chicago, IL, Nigeria; Centre for Population & Reproductive Health, College of Medicine, University of Ibadan, Ibadan, Oyo, Nigeria
| | - N Ibrahim
- Center for Global Health, The University of Chicago, Chicago, IL; Institute for Genomics and Systems Biology, The University of Chicago, Chicago, IL; Novartis Institutes for BioMedical Research, Cambridge, MA; Institute for Advanced Medical Research and Training, College of Medicine, University of Ibadan, Ibadan, Oyo, Nigeria; University of Ibadan, Ibadan, Oyo, Nigeria; Lagos State University Teaching Hospital, Ikeja, Lagos, Nigeria; Oncology Unit, Lagos State University, Ikeja, Lagos, Nigeria; The University of Chicago, Chicago, IL, Nigeria; Centre for Population & Reproductive Health, College of Medicine, University of Ibadan, Ibadan, Oyo, Nigeria
| | - O Oluwasola
- Center for Global Health, The University of Chicago, Chicago, IL; Institute for Genomics and Systems Biology, The University of Chicago, Chicago, IL; Novartis Institutes for BioMedical Research, Cambridge, MA; Institute for Advanced Medical Research and Training, College of Medicine, University of Ibadan, Ibadan, Oyo, Nigeria; University of Ibadan, Ibadan, Oyo, Nigeria; Lagos State University Teaching Hospital, Ikeja, Lagos, Nigeria; Oncology Unit, Lagos State University, Ikeja, Lagos, Nigeria; The University of Chicago, Chicago, IL, Nigeria; Centre for Population & Reproductive Health, College of Medicine, University of Ibadan, Ibadan, Oyo, Nigeria
| | - J Barretina
- Center for Global Health, The University of Chicago, Chicago, IL; Institute for Genomics and Systems Biology, The University of Chicago, Chicago, IL; Novartis Institutes for BioMedical Research, Cambridge, MA; Institute for Advanced Medical Research and Training, College of Medicine, University of Ibadan, Ibadan, Oyo, Nigeria; University of Ibadan, Ibadan, Oyo, Nigeria; Lagos State University Teaching Hospital, Ikeja, Lagos, Nigeria; Oncology Unit, Lagos State University, Ikeja, Lagos, Nigeria; The University of Chicago, Chicago, IL, Nigeria; Centre for Population & Reproductive Health, College of Medicine, University of Ibadan, Ibadan, Oyo, Nigeria
| |
Collapse
|
6
|
Olopade OI, Odetunde A, Riester M, Yoshimatsu T, Labrot E, Ademola A, Sanni A, Okedere B, Mahan S, Nwosu I, Leary R, Ajani M, Johnson RS, Sveen E, Zheng Y, Clayton W, Khramtsova G, Oludara M, Omodele F, Benson O, Adeoye A, Morhason-Bello O, Ogundiran T, Babalola C, Popoola A, Morrissey M, Huo D, Falusi A, Winckler W, Obafunwa J, Papoutsakis D, Ojengbede O, Ibrahim N, Oluwasola O, Barretina J. Abstract P6-03-17: Genomic landscape of breast cancers from women of African ancestry across the diaspora. Cancer Res 2016. [DOI: 10.1158/1538-7445.sabcs15-p6-03-17] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Objectives: Of all ethnic/racial groups, age-standardized mortality rate from breast cancer is highest for African American women in the US for reasons that remain understudied. The paucity of genomic studies of breast tumors across the African Diaspora further restricts our understanding of the biology of breast cancer in underserved populations. To gain a better understanding of the genomic landscape of breast cancer in women of African Ancestry, we have developed a cross continent translational research infrastructure to examine the spectrum of genetic alterations in breast tumors from West Africa compared to the spectrum of alterations observed in tumors from African-American and other women who are predominantly white in The Cancer Genome Atlas (TCGA) dataset.
Methods: Peripheral blood and breast cancer biopsy tissues were collected from 214 patients enrolled in the West Africa Breast Cancer Study (WABCS) at the University of Ibadan/University College Hospital (UI/UCH) and at Lagos State University Teaching Hospital (LASUTH). Blood DNA as well as breast cancer tissue DNA and RNA were extracted at the Novartis Institutes for Biomedical Research (NIBR), UI/UCH, and LASUTH using a modified protocol of PAXgene Tissue DNA and RNA extraction method. Whole-exome (WES) and transcriptome (RNA-seq) sequencing were performed on the Illumina HiSeq2000 platform at NIBR. Single Nucleotide Variants (SNVs) and insertions/deletions (indels) were called using MuTect and Pindel, while Copy Number Alterations (CNAs) were called using an in-house implementation of the ABSOLUTE method. Observed mutations were compared against those reported in the TCGA dataset. ER, PR and HER2 status were determined by immunohistochemistry (IHC) at UI/UCH, LASUTH and UChicago.
Results: WES data for 95 tumors have been analyzed thus far. Genes commonly mutated in breast cancer in TCGA are also mutated in WABCS but the mutational spectrum is vastly different. TP53 (64%), MYC (31%), and GATA3 (26%), showed significantly higher alteration frequencies in WABCS and African Americans. In contrast, PIK3CA (20%), CDH1 (2%), and MAP3K1 (2%) were less frequently mutated in women of African ancestry. In addition to the high proportion with TP53 mutations, the proportion with HER2 positive subtype of 42.1% and triple-negative subtype of 37.9% suggest that tumors with the most aggressive features are overrepresented in breast cancer patients in West Africa.
Conclusions: In the first study of its kind, high throughput genomic analysis of the largest cohort of women of African ancestry has uncovered alterations in cancer genes, some of which may be amenable to treatment with targeted therapies. Furthermore, we provide evidence that population differences in frequency and spectrum of mutations should drive the design and deployment of precision medicine initiatives. Only then can we develop innovative interventions to reduce the unacceptably high rates of mortality from breast cancer in underserved and under resourced populations.
Citation Format: Olopade OI, Odetunde A, Riester M, Yoshimatsu T, Labrot E, Ademola A, Sanni A, Okedere B, Mahan S, Nwosu I, Leary R, Ajani M, Johnson RS, Sveen E, Zheng Y, Clayton W, Khramtsova G, Oludara M, Omodele F, Benson O, Adeoye A, Morhason-Bello O, Ogundiran T, Babalola C, Popoola A, Morrissey M, Huo D, Falusi A, Winckler W, Obafunwa J, Papoutsakis D, Ojengbede O, Ibrahim N, Oluwasola O, Barretina J. Genomic landscape of breast cancers from women of African ancestry across the diaspora. [abstract]. In: Proceedings of the Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2015 Dec 8-12; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2016;76(4 Suppl):Abstract nr P6-03-17.
Collapse
Affiliation(s)
- OI Olopade
- The University of Chicago, Chicago, IL; Institute for Advanced Medical Research and Training, College of Medicine, University of Ibadan, Ibadan, Oyo, Nigeria; Novartis Institutes for BioMedical Research, Cambridge, MA; University of Ibadan, Ibadan, Oyo, Nigeria; Lagos State University Teaching Hospital, Ikeja, Lagos, Nigeria; Lagos State University, Ikeja, Lagos, Nigeria
| | - A Odetunde
- The University of Chicago, Chicago, IL; Institute for Advanced Medical Research and Training, College of Medicine, University of Ibadan, Ibadan, Oyo, Nigeria; Novartis Institutes for BioMedical Research, Cambridge, MA; University of Ibadan, Ibadan, Oyo, Nigeria; Lagos State University Teaching Hospital, Ikeja, Lagos, Nigeria; Lagos State University, Ikeja, Lagos, Nigeria
| | - M Riester
- The University of Chicago, Chicago, IL; Institute for Advanced Medical Research and Training, College of Medicine, University of Ibadan, Ibadan, Oyo, Nigeria; Novartis Institutes for BioMedical Research, Cambridge, MA; University of Ibadan, Ibadan, Oyo, Nigeria; Lagos State University Teaching Hospital, Ikeja, Lagos, Nigeria; Lagos State University, Ikeja, Lagos, Nigeria
| | - T Yoshimatsu
- The University of Chicago, Chicago, IL; Institute for Advanced Medical Research and Training, College of Medicine, University of Ibadan, Ibadan, Oyo, Nigeria; Novartis Institutes for BioMedical Research, Cambridge, MA; University of Ibadan, Ibadan, Oyo, Nigeria; Lagos State University Teaching Hospital, Ikeja, Lagos, Nigeria; Lagos State University, Ikeja, Lagos, Nigeria
| | - E Labrot
- The University of Chicago, Chicago, IL; Institute for Advanced Medical Research and Training, College of Medicine, University of Ibadan, Ibadan, Oyo, Nigeria; Novartis Institutes for BioMedical Research, Cambridge, MA; University of Ibadan, Ibadan, Oyo, Nigeria; Lagos State University Teaching Hospital, Ikeja, Lagos, Nigeria; Lagos State University, Ikeja, Lagos, Nigeria
| | - A Ademola
- The University of Chicago, Chicago, IL; Institute for Advanced Medical Research and Training, College of Medicine, University of Ibadan, Ibadan, Oyo, Nigeria; Novartis Institutes for BioMedical Research, Cambridge, MA; University of Ibadan, Ibadan, Oyo, Nigeria; Lagos State University Teaching Hospital, Ikeja, Lagos, Nigeria; Lagos State University, Ikeja, Lagos, Nigeria
| | - A Sanni
- The University of Chicago, Chicago, IL; Institute for Advanced Medical Research and Training, College of Medicine, University of Ibadan, Ibadan, Oyo, Nigeria; Novartis Institutes for BioMedical Research, Cambridge, MA; University of Ibadan, Ibadan, Oyo, Nigeria; Lagos State University Teaching Hospital, Ikeja, Lagos, Nigeria; Lagos State University, Ikeja, Lagos, Nigeria
| | - B Okedere
- The University of Chicago, Chicago, IL; Institute for Advanced Medical Research and Training, College of Medicine, University of Ibadan, Ibadan, Oyo, Nigeria; Novartis Institutes for BioMedical Research, Cambridge, MA; University of Ibadan, Ibadan, Oyo, Nigeria; Lagos State University Teaching Hospital, Ikeja, Lagos, Nigeria; Lagos State University, Ikeja, Lagos, Nigeria
| | - S Mahan
- The University of Chicago, Chicago, IL; Institute for Advanced Medical Research and Training, College of Medicine, University of Ibadan, Ibadan, Oyo, Nigeria; Novartis Institutes for BioMedical Research, Cambridge, MA; University of Ibadan, Ibadan, Oyo, Nigeria; Lagos State University Teaching Hospital, Ikeja, Lagos, Nigeria; Lagos State University, Ikeja, Lagos, Nigeria
| | - I Nwosu
- The University of Chicago, Chicago, IL; Institute for Advanced Medical Research and Training, College of Medicine, University of Ibadan, Ibadan, Oyo, Nigeria; Novartis Institutes for BioMedical Research, Cambridge, MA; University of Ibadan, Ibadan, Oyo, Nigeria; Lagos State University Teaching Hospital, Ikeja, Lagos, Nigeria; Lagos State University, Ikeja, Lagos, Nigeria
| | - R Leary
- The University of Chicago, Chicago, IL; Institute for Advanced Medical Research and Training, College of Medicine, University of Ibadan, Ibadan, Oyo, Nigeria; Novartis Institutes for BioMedical Research, Cambridge, MA; University of Ibadan, Ibadan, Oyo, Nigeria; Lagos State University Teaching Hospital, Ikeja, Lagos, Nigeria; Lagos State University, Ikeja, Lagos, Nigeria
| | - M Ajani
- The University of Chicago, Chicago, IL; Institute for Advanced Medical Research and Training, College of Medicine, University of Ibadan, Ibadan, Oyo, Nigeria; Novartis Institutes for BioMedical Research, Cambridge, MA; University of Ibadan, Ibadan, Oyo, Nigeria; Lagos State University Teaching Hospital, Ikeja, Lagos, Nigeria; Lagos State University, Ikeja, Lagos, Nigeria
| | - RS Johnson
- The University of Chicago, Chicago, IL; Institute for Advanced Medical Research and Training, College of Medicine, University of Ibadan, Ibadan, Oyo, Nigeria; Novartis Institutes for BioMedical Research, Cambridge, MA; University of Ibadan, Ibadan, Oyo, Nigeria; Lagos State University Teaching Hospital, Ikeja, Lagos, Nigeria; Lagos State University, Ikeja, Lagos, Nigeria
| | - E Sveen
- The University of Chicago, Chicago, IL; Institute for Advanced Medical Research and Training, College of Medicine, University of Ibadan, Ibadan, Oyo, Nigeria; Novartis Institutes for BioMedical Research, Cambridge, MA; University of Ibadan, Ibadan, Oyo, Nigeria; Lagos State University Teaching Hospital, Ikeja, Lagos, Nigeria; Lagos State University, Ikeja, Lagos, Nigeria
| | - Y Zheng
- The University of Chicago, Chicago, IL; Institute for Advanced Medical Research and Training, College of Medicine, University of Ibadan, Ibadan, Oyo, Nigeria; Novartis Institutes for BioMedical Research, Cambridge, MA; University of Ibadan, Ibadan, Oyo, Nigeria; Lagos State University Teaching Hospital, Ikeja, Lagos, Nigeria; Lagos State University, Ikeja, Lagos, Nigeria
| | - W Clayton
- The University of Chicago, Chicago, IL; Institute for Advanced Medical Research and Training, College of Medicine, University of Ibadan, Ibadan, Oyo, Nigeria; Novartis Institutes for BioMedical Research, Cambridge, MA; University of Ibadan, Ibadan, Oyo, Nigeria; Lagos State University Teaching Hospital, Ikeja, Lagos, Nigeria; Lagos State University, Ikeja, Lagos, Nigeria
| | - G Khramtsova
- The University of Chicago, Chicago, IL; Institute for Advanced Medical Research and Training, College of Medicine, University of Ibadan, Ibadan, Oyo, Nigeria; Novartis Institutes for BioMedical Research, Cambridge, MA; University of Ibadan, Ibadan, Oyo, Nigeria; Lagos State University Teaching Hospital, Ikeja, Lagos, Nigeria; Lagos State University, Ikeja, Lagos, Nigeria
| | - M Oludara
- The University of Chicago, Chicago, IL; Institute for Advanced Medical Research and Training, College of Medicine, University of Ibadan, Ibadan, Oyo, Nigeria; Novartis Institutes for BioMedical Research, Cambridge, MA; University of Ibadan, Ibadan, Oyo, Nigeria; Lagos State University Teaching Hospital, Ikeja, Lagos, Nigeria; Lagos State University, Ikeja, Lagos, Nigeria
| | - F Omodele
- The University of Chicago, Chicago, IL; Institute for Advanced Medical Research and Training, College of Medicine, University of Ibadan, Ibadan, Oyo, Nigeria; Novartis Institutes for BioMedical Research, Cambridge, MA; University of Ibadan, Ibadan, Oyo, Nigeria; Lagos State University Teaching Hospital, Ikeja, Lagos, Nigeria; Lagos State University, Ikeja, Lagos, Nigeria
| | - O Benson
- The University of Chicago, Chicago, IL; Institute for Advanced Medical Research and Training, College of Medicine, University of Ibadan, Ibadan, Oyo, Nigeria; Novartis Institutes for BioMedical Research, Cambridge, MA; University of Ibadan, Ibadan, Oyo, Nigeria; Lagos State University Teaching Hospital, Ikeja, Lagos, Nigeria; Lagos State University, Ikeja, Lagos, Nigeria
| | - A Adeoye
- The University of Chicago, Chicago, IL; Institute for Advanced Medical Research and Training, College of Medicine, University of Ibadan, Ibadan, Oyo, Nigeria; Novartis Institutes for BioMedical Research, Cambridge, MA; University of Ibadan, Ibadan, Oyo, Nigeria; Lagos State University Teaching Hospital, Ikeja, Lagos, Nigeria; Lagos State University, Ikeja, Lagos, Nigeria
| | - O Morhason-Bello
- The University of Chicago, Chicago, IL; Institute for Advanced Medical Research and Training, College of Medicine, University of Ibadan, Ibadan, Oyo, Nigeria; Novartis Institutes for BioMedical Research, Cambridge, MA; University of Ibadan, Ibadan, Oyo, Nigeria; Lagos State University Teaching Hospital, Ikeja, Lagos, Nigeria; Lagos State University, Ikeja, Lagos, Nigeria
| | - T Ogundiran
- The University of Chicago, Chicago, IL; Institute for Advanced Medical Research and Training, College of Medicine, University of Ibadan, Ibadan, Oyo, Nigeria; Novartis Institutes for BioMedical Research, Cambridge, MA; University of Ibadan, Ibadan, Oyo, Nigeria; Lagos State University Teaching Hospital, Ikeja, Lagos, Nigeria; Lagos State University, Ikeja, Lagos, Nigeria
| | - C Babalola
- The University of Chicago, Chicago, IL; Institute for Advanced Medical Research and Training, College of Medicine, University of Ibadan, Ibadan, Oyo, Nigeria; Novartis Institutes for BioMedical Research, Cambridge, MA; University of Ibadan, Ibadan, Oyo, Nigeria; Lagos State University Teaching Hospital, Ikeja, Lagos, Nigeria; Lagos State University, Ikeja, Lagos, Nigeria
| | - A Popoola
- The University of Chicago, Chicago, IL; Institute for Advanced Medical Research and Training, College of Medicine, University of Ibadan, Ibadan, Oyo, Nigeria; Novartis Institutes for BioMedical Research, Cambridge, MA; University of Ibadan, Ibadan, Oyo, Nigeria; Lagos State University Teaching Hospital, Ikeja, Lagos, Nigeria; Lagos State University, Ikeja, Lagos, Nigeria
| | - M Morrissey
- The University of Chicago, Chicago, IL; Institute for Advanced Medical Research and Training, College of Medicine, University of Ibadan, Ibadan, Oyo, Nigeria; Novartis Institutes for BioMedical Research, Cambridge, MA; University of Ibadan, Ibadan, Oyo, Nigeria; Lagos State University Teaching Hospital, Ikeja, Lagos, Nigeria; Lagos State University, Ikeja, Lagos, Nigeria
| | - D Huo
- The University of Chicago, Chicago, IL; Institute for Advanced Medical Research and Training, College of Medicine, University of Ibadan, Ibadan, Oyo, Nigeria; Novartis Institutes for BioMedical Research, Cambridge, MA; University of Ibadan, Ibadan, Oyo, Nigeria; Lagos State University Teaching Hospital, Ikeja, Lagos, Nigeria; Lagos State University, Ikeja, Lagos, Nigeria
| | - A Falusi
- The University of Chicago, Chicago, IL; Institute for Advanced Medical Research and Training, College of Medicine, University of Ibadan, Ibadan, Oyo, Nigeria; Novartis Institutes for BioMedical Research, Cambridge, MA; University of Ibadan, Ibadan, Oyo, Nigeria; Lagos State University Teaching Hospital, Ikeja, Lagos, Nigeria; Lagos State University, Ikeja, Lagos, Nigeria
| | - W Winckler
- The University of Chicago, Chicago, IL; Institute for Advanced Medical Research and Training, College of Medicine, University of Ibadan, Ibadan, Oyo, Nigeria; Novartis Institutes for BioMedical Research, Cambridge, MA; University of Ibadan, Ibadan, Oyo, Nigeria; Lagos State University Teaching Hospital, Ikeja, Lagos, Nigeria; Lagos State University, Ikeja, Lagos, Nigeria
| | - J Obafunwa
- The University of Chicago, Chicago, IL; Institute for Advanced Medical Research and Training, College of Medicine, University of Ibadan, Ibadan, Oyo, Nigeria; Novartis Institutes for BioMedical Research, Cambridge, MA; University of Ibadan, Ibadan, Oyo, Nigeria; Lagos State University Teaching Hospital, Ikeja, Lagos, Nigeria; Lagos State University, Ikeja, Lagos, Nigeria
| | - D Papoutsakis
- The University of Chicago, Chicago, IL; Institute for Advanced Medical Research and Training, College of Medicine, University of Ibadan, Ibadan, Oyo, Nigeria; Novartis Institutes for BioMedical Research, Cambridge, MA; University of Ibadan, Ibadan, Oyo, Nigeria; Lagos State University Teaching Hospital, Ikeja, Lagos, Nigeria; Lagos State University, Ikeja, Lagos, Nigeria
| | - O Ojengbede
- The University of Chicago, Chicago, IL; Institute for Advanced Medical Research and Training, College of Medicine, University of Ibadan, Ibadan, Oyo, Nigeria; Novartis Institutes for BioMedical Research, Cambridge, MA; University of Ibadan, Ibadan, Oyo, Nigeria; Lagos State University Teaching Hospital, Ikeja, Lagos, Nigeria; Lagos State University, Ikeja, Lagos, Nigeria
| | - N Ibrahim
- The University of Chicago, Chicago, IL; Institute for Advanced Medical Research and Training, College of Medicine, University of Ibadan, Ibadan, Oyo, Nigeria; Novartis Institutes for BioMedical Research, Cambridge, MA; University of Ibadan, Ibadan, Oyo, Nigeria; Lagos State University Teaching Hospital, Ikeja, Lagos, Nigeria; Lagos State University, Ikeja, Lagos, Nigeria
| | - O Oluwasola
- The University of Chicago, Chicago, IL; Institute for Advanced Medical Research and Training, College of Medicine, University of Ibadan, Ibadan, Oyo, Nigeria; Novartis Institutes for BioMedical Research, Cambridge, MA; University of Ibadan, Ibadan, Oyo, Nigeria; Lagos State University Teaching Hospital, Ikeja, Lagos, Nigeria; Lagos State University, Ikeja, Lagos, Nigeria
| | - J Barretina
- The University of Chicago, Chicago, IL; Institute for Advanced Medical Research and Training, College of Medicine, University of Ibadan, Ibadan, Oyo, Nigeria; Novartis Institutes for BioMedical Research, Cambridge, MA; University of Ibadan, Ibadan, Oyo, Nigeria; Lagos State University Teaching Hospital, Ikeja, Lagos, Nigeria; Lagos State University, Ikeja, Lagos, Nigeria
| |
Collapse
|
7
|
MacRae S, Lewis J, Morrissey M, Critchley D, Shortland A. Does footwear have a long-term influence on postural stability in chronic low back pain? Physiotherapy 2015. [DOI: 10.1016/j.physio.2015.03.1766] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
8
|
MacRae S, Lewis J, Shortland A, Morrissey M, Critchley D. Rocker sole shoes are no more beneficial than flat sole shoes in the management of chronic low back pain. Physiotherapy 2015. [DOI: 10.1016/j.physio.2015.03.1765] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
9
|
Vogel BH, Bradley SE, Adams DJ, D'Aco K, Erbe RW, Fong C, Iglesias A, Kronn D, Levy P, Morrissey M, Orsini J, Parton P, Pellegrino J, Saavedra-Matiz CA, Shur N, Wasserstein M, Raymond GV, Caggana M. Newborn screening for X-linked adrenoleukodystrophy in New York State: diagnostic protocol, surveillance protocol and treatment guidelines. Mol Genet Metab 2015; 114:599-603. [PMID: 25724074 DOI: 10.1016/j.ymgme.2015.02.002] [Citation(s) in RCA: 82] [Impact Index Per Article: 9.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/09/2014] [Revised: 02/05/2015] [Accepted: 02/05/2015] [Indexed: 11/24/2022]
Abstract
PURPOSE To describe a diagnostic protocol, surveillance and treatment guidelines, genetic counseling considerations and long-term follow-up data elements developed in preparation for X-linked adrenoleukodystrophy (X-ALD) newborn screening in New York State. METHODS A group including the director from each regional NYS inherited metabolic disorder center, personnel from the NYS Newborn Screening Program, and others prepared a follow-up plan for X-ALD NBS. Over the months preceding the start of screening, a series of conference calls took place to develop and refine a complete newborn screening system from initial positive screen results to long-term follow-up. RESULTS A diagnostic protocol was developed to determine for each newborn with a positive screen whether the final diagnosis is X-ALD, carrier of X-ALD, Zellweger spectrum disorder, acyl CoA oxidase deficiency or D-bifunctional protein deficiency. For asymptomatic males with X-ALD, surveillance protocols were developed for use at the time of diagnosis, during childhood and during adulthood. Considerations for timing of treatment of adrenal and cerebral disease were developed. CONCLUSION Because New York was the first newborn screening laboratory to include X-ALD on its panel, and symptoms may not develop for years, long-term follow-up is needed to evaluate the presented guidelines.
Collapse
Affiliation(s)
- B H Vogel
- Newborn Screening Program, Wadsworth Center, New York State Department of Health, Albany, NY, USA.
| | - S E Bradley
- Newborn Screening Program, Wadsworth Center, New York State Department of Health, Albany, NY, USA
| | - D J Adams
- Jacobs Equity Management Personalized Genomic Medicine Program, Goryeb Pediatrics Genetics and Metabolism, Morristown, NJ, USA
| | - K D'Aco
- Department of Pediatrics, University of Rochester Medical Center, Rochester, NY, USA
| | - R W Erbe
- Division of Genetics, Women and Children's Hospital of Buffalo, Buffalo, NY, USA
| | - C Fong
- Department of Pediatrics, University of Rochester Medical Center, Rochester, NY, USA
| | - A Iglesias
- New York Presbyterian Morgan Stanley Children's Hospital, New York, NY, USA
| | - D Kronn
- New York Medical College, Valhalla, NY, USA
| | - P Levy
- Center for Inherited Medical Disorders, Children's Hospital at Montefiore, Bronx, NY, USA
| | - M Morrissey
- Newborn Screening Program, Wadsworth Center, New York State Department of Health, Albany, NY, USA
| | - J Orsini
- Newborn Screening Program, Wadsworth Center, New York State Department of Health, Albany, NY, USA
| | - P Parton
- Division of Genetics, Stony Brook Long Island Children's Hospital, Stony Brook, NY, USA
| | - J Pellegrino
- Department of Pediatrics, State University of New York Upstate Medical University, Syracuse, NY, USA
| | - C A Saavedra-Matiz
- Newborn Screening Program, Wadsworth Center, New York State Department of Health, Albany, NY, USA
| | - N Shur
- Albany Medical Center, Albany, NY, USA
| | - M Wasserstein
- Division of Medical Genetics, Division of Genomic Sciences, Mount Sinai Medical Center, New York, NY, USA
| | - G V Raymond
- Department of Neurology, University of Minnesota Medical Center, Minneapolis, MN, USA
| | - M Caggana
- Newborn Screening Program, Wadsworth Center, New York State Department of Health, Albany, NY, USA
| |
Collapse
|
10
|
Wang F, Annaheim S, Morrissey M, Rossi RM. Real evaporative cooling efficiency of one-layer tight-fitting sportswear in a hot environment. Scand J Med Sci Sports 2013; 24:e129-39. [DOI: 10.1111/sms.12117] [Citation(s) in RCA: 42] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 07/27/2013] [Indexed: 11/29/2022]
Affiliation(s)
- F. Wang
- Laboratory for Protection and Physiology; EMPA-Swiss Federal Laboratories for Materials Science and Technology; St. Gallen Switzerland
| | - S. Annaheim
- Laboratory for Protection and Physiology; EMPA-Swiss Federal Laboratories for Materials Science and Technology; St. Gallen Switzerland
| | - M. Morrissey
- Laboratory for Protection and Physiology; EMPA-Swiss Federal Laboratories for Materials Science and Technology; St. Gallen Switzerland
| | - R. M. Rossi
- Laboratory for Protection and Physiology; EMPA-Swiss Federal Laboratories for Materials Science and Technology; St. Gallen Switzerland
| |
Collapse
|
11
|
Tobias J, Deere K, Palmer S, Clark E, Clinch J, Fikree A, Aktar R, Wellstead G, Knowles C, Grahame R, Aziz Q, Amaral B, Murphy G, Ioannou Y, Isenberg DA, Tansley SL, Betteridge ZE, Gunawardena H, Shaddick G, Varsani H, Wedderburn L, McHugh N, De Benedetti F, Ruperto N, Espada G, Gerloni V, Flato B, Horneff G, Myones BL, Onel K, Frane J, Kenwright A, Lipman TH, Bharucha KN, Martini A, Lovell DJ, Baildam E, Ruperto N, Brunner H, Zuber Z, Keane C, Harari O, Kenwright A, Cuttica RJ, Keltsev V, Xavier R, Penades IC, Nikishina I, Rubio-Perez N, Alekseeva E, Chasnyk V, Chavez J, Horneff G, Opoka-Winiarska V, Quartier P, Silva CA, Silverman ED, Spindler A, Lovell DJ, Martini A, De Benedetti F, Hendry GJ, Watt GF, Brandon M, Friel L, Turner D, Lorgelly PK, Gardner-Medwin J, Sturrock RD, Woodburn J, Firth J, Waxman R, Law G, Siddle H, Nelson AE, Helliwell P, Otter S, Butters V, Loughrey L, Alcacer-Pitarch B, Tranter J, Davies S, Hryniw R, Lewis S, Baker L, Dures E, Hewlett S, Ambler N, Clarke J, Gooberman-Hill R, Jenkins R, Wilkie R, Bucknall M, Jordan K, McBeth J, Norton S, Walsh D, Kiely P, Williams R, Young A, Harkess JE, McAlarey K, Chesterton L, van der Windt DA, Sim J, Lewis M, Mallen CD, Mason E, Hay E, Clarson LE, Hider SL, Belcher J, Heneghan C, Roddy E, Mallen CD, Gibson J, Whiteford S, Williamson E, Beatty S, Hamilton-Dyer N, Healey EL, Ryan S, McHugh GA, Main CJ, Porcheret M, Nio Ong B, Pushpa-Rajah A, Dziedzic KS, MacRae CS, Shortland A, Lewis J, Morrissey M, Critchley D, Muller S, Mallen CD, Belcher J, Helliwell T, Hider SL, Cole Z, Parsons C, Crozier S, Robinson S, Taylor P, Inskip H, Godfrey K, Dennison E, Harvey NC, Cooper C, Prieto Alhambra D, Lalmohamed A, Abrahamsen B, Arden N, de Boer A, Vestergaard P, de Vries F, Kendal A, Carr A, Prieto-Alhambra D, Judge A, Cooper C, Chapurlat R, Bellamy N, Czerwinski E, Pierre Devogelaer J, March L, Pavelka K, Reginster JY, Kiran A, Judge A, Javaid MK, Arden N, Cooper C, Sundy JS, Baraf HS, Becker M, Treadwell EL, Yood R, Ottery FD. Oral Abstracts 3: Adolescent and Young Adult * O13. Hypermobility is a Risk Factor for Musculoskeletal Pain in Adolescence: Findings From a Prospective Cohort Study. Rheumatology (Oxford) 2013. [DOI: 10.1093/rheumatology/ket200] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
12
|
Jennings S, Bennett K, Cavanagh B, Morrissey M, Kearney P. HeartBeat--improving heart attack care. Ir Med J 2011; 104:9-12. [PMID: 21387877] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/30/2023]
Abstract
We aimed to save lives by assuring best practice in ST elevation myocardial infarction (STEMI) through initiating the Institute for Healthcare Improvement (IHI) methodology nationally. Following collection of a minimum dataset, annual change in indicators in the five initiating hospitals for the period Oct 2006 - Sept 2009 was assessed by analysing the percentage of patients receiving the eight components of evidenced based care on admission and discharge and in-hospital mortality rate. For 635 patients, performance on seven of the eight indicators of care exceeded 90% annually. Timely reperfusion therapy (thrombolysis, primary percutaneous coronary intervention (PPCI)) improved non-significantly from 68.2% (107 patients) in year 1 to 77.1% (118 patients) in year 3. In-hospital mortality declined significantly from 12.4% (24 deaths) in year 1 to 5% (9 deaths) in year 3. Evidence based STEMI care is followed to a high degree but timely reperfusion and PPCI provision remain a challenge nationally.
Collapse
Affiliation(s)
- S Jennings
- HSE--Department of Public Health, Dr Steeven's Hospital, James's St, Dublin 8.
| | | | | | | | | |
Collapse
|
13
|
Páez DJ, Morrissey M, Bernatchez L, Dodson JJ. The genetic basis of early-life morphological traits and their relation to alternative male reproductive tactics in Atlantic salmon. J Evol Biol 2010; 23:757-68. [PMID: 20149020 DOI: 10.1111/j.1420-9101.2010.01941.x] [Citation(s) in RCA: 27] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
Abstract
Although heritability estimates for traits potentially under natural selection are increasingly being reported, their estimation remains a challenge if we are to understand the patterns of adaptive phenotypic change in nature. Given the potentially important role of selection on the early life phenotype, and thereby on future life history events in many fish species, we conducted a common garden experiment, using the Atlantic salmon (Salmo salar L.), with two major aims. The first objective is to determine how the site of origin, the paternal sexual tactic and additive genetic effects influence phenotypic variation of several morphological traits at hatching and emergence. The second aim is to test whether a link exists between phenotypic characteristics early in life and the incidence of male alternative tactics later in life. We found no evidence of a site or paternal effect on any morphological trait at hatching or emergence, suggesting that the spatial phenotypic differences observed in the natural river system from which these fish originated are mainly environmentally driven. However, we do find significant heritabilities and maternal effects for several traits, including body size. No direct evidence was found correlating the incidence of precocious maturation with early life characteristics. We suggest that under good growing conditions, body size and other traits at early developmental stages are not reliable cues for the surpassing of the threshold values associated with male sexual development.
Collapse
Affiliation(s)
- D J Páez
- Québec-Océan and Centre Interuniversitaire de Recherche sur le Saumon Atlantique (CIRSA), Département de Biologie, Pavillon Alexandre-Vachon, Université Laval, Québec, Qc, Canada.
| | | | | | | |
Collapse
|
14
|
Morgan CL, McEwan P, Morrissey M, Peters JR, Poole C, Currie CJ. Characterization and comparison of health-related utility in people with diabetes with various single and multiple vascular complications. Diabet Med 2006; 23:1100-5. [PMID: 16978374 DOI: 10.1111/j.1464-5491.2006.01936.x] [Citation(s) in RCA: 27] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
Abstract
AIMS To characterize and compare health-related utility in a large cohort of patients treated in hospital with diabetes and with single and multiple comorbidities. METHODS The study was conducted in Cardiff and the Vale of Glamorgan, UK. Health-related utility was measured using the EQ5D(index), a standardized instrument for measuring health outcome. Patients from the Health Outcomes Data Repository (HODaR) were surveyed by postal questionnaire 6 weeks post discharge for in-patients and during clinics for patients attending as out-patients between January 2002 and July 2005. Patients with diabetes were identified by a previous history of in-patient admission with diabetes or as an out-patient with diabetes recorded as a coexisting diagnosis. RESULTS We identified 4502 patients with diabetes. Mean ages were 65.4 and 64.2 years for males and females, respectively. Of these, 2003 (45%) had no recorded vascular complication. Overall, the EQ5D(index) was 0.584 (sd 0.325) for males and 0.533 (sd 0.351) for females. For those without any vascular complications the mean EQ5D(index) was 0.735 (sd 0.288). In a general linear model, the presence of single and multiple complications had a detrimental impact on the EQ5D(index). CONCLUSION The results of this study provide an indication of the true impact of diabetes in terms of health-related utility. There was a decrease in the mean EQ5D(index) for those with vascular complications. Economic models of diabetes that have used additive or multiplicative methods to assess utility in individuals with several complications may be unreliable, and direct measurements, such as this, are recommended.
Collapse
Affiliation(s)
- C Ll Morgan
- Department of Medicine, School of Medicine, Cardiff University, Cardiff, UK
| | | | | | | | | | | |
Collapse
|
15
|
Lee AJ, Morgan CL, Morrissey M, Wittrup-Jensen KU, Kennedy-Martin T, Currie CJ. Evaluation of the association between the EQ-5D (health-related utility) and body mass index (obesity) in hospital-treated people with Type 1 diabetes, Type 2 diabetes and with no diagnosed diabetes. Diabet Med 2005; 22:1482-6. [PMID: 16241910 DOI: 10.1111/j.1464-5491.2005.01657.x] [Citation(s) in RCA: 65] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
AIMS The purpose of this study was to characterize the impact of body mass index (BMI) on health-related utility for patients with Type 1 and Type 2 diabetes and those without diabetes. METHODS The study was conducted in Cardiff and the Vale of Glamorgan, Wales, UK. Health-related utility was measured using the EQ-5D(index). Patients from the Health Outcomes Data Repository (HODaR) were surveyed by postal questionnaire either 6 weeks post discharge for in-patients or at out-patient clinics between January 2002 and July 2003. BMI was calculated from self-reported data within the survey. Patients with diabetes were identified by a previous history of an in-patient admission with diabetes or as an out-patient with diabetes recorded as a coexisting diagnosis. RESULTS Questionnaires were returned from 27 924 patients of whom 2575 had diabetes. Increasing BMI was found to reduce utility in all three groups. BMI was significantly greater for those with Type 2 diabetes compared with those with Type 1, and those without diabetes (P < 0.001). Multiple regression analysis demonstrated that both BMI and diabetes status had a significant effect on utility. However, the rate of change of utility attributable to BMI was not found to be significantly different between the various groups. CONCLUSIONS Obesity negatively impacts upon health-related utility and thus quality of life for all patient groups. There was no significant difference in the effect of obesity on utility between those with and without diabetes.
Collapse
Affiliation(s)
- A J Lee
- Cardiff Research Consortium, University Hospital of Wales, Cardiff CF14 4UJ, Wales, UK
| | | | | | | | | | | |
Collapse
|
16
|
Abstract
OBJECTIVE To gain an insight into children's views about food and nutrition. DESIGN Data were collected in focus group discussions; two focus group sessions were undertaken with each school group. SETTING A total of 11 postprimary schools in Northern Ireland and England. SUBJECTS In all, 106 children aged 11-12-y-old (n = 52 boys, n = 54 girls). RESULTS Focus group transcripts were analysed using qualitative research methodology. Major barriers to healthy eating were taste, appearance of food, filling power, time/effort, cost, choice/availability, risk, rebellion, and body image/weight concerns. The main difference between sexes was in terms of motivating factors for eating well; girls tended to focus primarily on their appearance whereas boys appeared to be more influenced by sport. There was some mention of balance and variety within the focus group discussions, however, in practice, the children had a tendency to categorise foods as either 'good' or 'bad', 'healthy' or 'unhealthy'. CONCLUSIONS This study has revealed a number of barriers to, and motivations for, healthy eating, which should be taken into account when planning nutrition intervention strategies aimed at children moving into adolescence. While it may be possible to immediately attempt to address some of the barriers identified in this study, for example, in nutrition education initiatives, other barriers (such as the lack of available, attractive and affordable healthy foods in the school canteen) will prove more difficult to tackle without changes at the policy level. Overall, it appears that health promotion specialists have a major challenge ahead in order to encourage this age group to view healthy eating as an attractive and achievable behaviour. SPONSORSHIP Food Standards Agency, London, UK.
Collapse
Affiliation(s)
- M C McKinley
- Northern Ireland Centre for Food and Health (NICHE), University of Ulster, Coleraine, Northern Ireland, BT52 1SA, UK
| | | | | | | | | | | | | |
Collapse
|
17
|
Cotler SJ, Reddy KR, McCone J, Wolfe DL, Liu A, Craft TR, Ferris MW, Conrad AJ, Albrecht J, Morrissey M, Ganger DR, Rosenblate H, Blatt LM, Jensen DM, Taylor MW. An analysis of acute changes in interleukin-6 levels after treatment of hepatitis C with consensus interferon. J Interferon Cytokine Res 2001; 21:1011-9. [PMID: 11798458 DOI: 10.1089/107999001317205132] [Citation(s) in RCA: 20] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Cytokine production has been implicated in the antiviral response to interferon-alpha (IFN-alpha) in hepatitis C and in the development of IFN-alpha-related side effects. We characterized acute changes in serum cytokine levels following administration of a single dose of consensus IFN (IFN-con1) and during continuous treatment of chronic hepatitis C patients. Serum samples were collected at baseline, at multiple times early after IFN administration, and weekly thereafter. Viral RNA titers were assessed by RT-PCR, and viral kinetics were followed. ELISA assays were used to measure IFN-gamma, tumor necrosis factor-alpha (TNF-alpha), interleukin-2 (IL-2), IL-4, IL-6, and IL-16. Serum cytokine levels were low at baseline. IL-6 was detected in patients with hepatitis C but not in healthy control subjects by either ELISA or RT-PCR, indicating that low levels of circulating IL-6 were associated with hepatitis C infection. None of the cytokines measured increased significantly after IFN administration except for IL-6. IL-6 levels rose rapidly, peaked at 6-15 h in a dose-dependent manner, and returned to baseline by 48 h in both patients receiving a single dose of IFN and those receiving continuous treatment. This was confirmed by RT-PCR. Pretreatment IL-6 levels were directly correlated with area under the curve (AUC) for IL-6 during the 24 h after IFN dosing (r = 0.611, p = 0.007). Viral titers decreased within 24-48 h after a single dose of IFN-con1. Changes in hepatitis C RNA titers were not significantly associated with pretreatment IL-6 levels or with changes in IL-6 levels. In conclusion, (1) baseline serum cytokine levels, except for IL-6, were low or within the normal range in patients with hepatitis C, (2) IL-6 levels were detected in some patients with hepatitis C before treatment but not in healthy controls, (3) IL-6 levels increased acutely after a single dose of IFN-alpha, and IL-6 induction was related to baseline IL-6 level, and (4) changes in IL-6 levels did not correlate with the early virologic response to IFN.
Collapse
Affiliation(s)
- S J Cotler
- Section of Hepatology and Department of Preventive Medicine, Rush-Presbyterian-St. Luke's Medical Center, Chicago, IL 60612, USA
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
18
|
Morrissey M, Wiles J. We can work it out. Nurs Times 2001; 97:34-6. [PMID: 11966261] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 04/18/2023]
|
19
|
Markmann JF, Markmann JW, Markmann DA, Bacquerizo A, Singer J, Holt CD, Gornbein J, Yersiz H, Morrissey M, Lerner SM, McDiarmid SV, Busuttil RW. Preoperative factors associated with outcome and their impact on resource use in 1148 consecutive primary liver transplants. Transplantation 2001; 72:1113-22. [PMID: 11579310 DOI: 10.1097/00007890-200109270-00023] [Citation(s) in RCA: 154] [Impact Index Per Article: 6.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/25/2023]
Abstract
BACKGROUND Hepatic transplantation is a highly effective but costly treatment for end-stage hepatic dysfunction. One approach to improve efficiency in the use of scarce organs for transplantation is to identify preoperative factors that are associated with poor outcome posttransplantation. This may assist both in selecting patients optimal for transplantation and in identifying strategies to improve survival. METHODS In the present work, we retrospectively reviewed consecutive liver transplants performed at the University of California at Los Angeles during a 6-year period and determined preoperative variables that were associated with outcome in primary grafts. In addition, we used the hospital's cost accounting database to determine the impact of these variables on the degree of resource use by high-risk patients. RESULTS We found five variables to have independent prognostic value in predicting graft survival after primary liver transplantation: (1) donor age, (2) recipient age, (3) donor sodium, (4) recipient creatinine, and (5) recipient ventilator requirement pretransplant. Recipient ventilator requirement and elevated creatinine were associated with significant increases in resource use during the transplant admission. CONCLUSIONS Patients at high risk for graft failure and costly transplants can be identified preoperatively by a set of parameters that are readily available, noninvasive, and inexpensive. Selection of recipients on the basis of these data would improve the efficiency of liver transplantation and reduce its cost.
Collapse
Affiliation(s)
- J F Markmann
- Harrison Department of Surgical Research, Hospital of the University of Pennsylvania, Philadelphia, USA
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
20
|
Shridhar V, Lee J, Pandita A, Iturria S, Avula R, Staub J, Morrissey M, Calhoun E, Sen A, Kalli K, Keeney G, Roche P, Cliby W, Lu K, Schmandt R, Mills GB, Bast RC, James CD, Couch FJ, Hartmann LC, Lillie J, Smith DI. Genetic analysis of early- versus late-stage ovarian tumors. Cancer Res 2001; 61:5895-904. [PMID: 11479231] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/20/2023]
Abstract
In the United States, ovarian cancer is the fourth most common cause of cancer-related deaths among women. The most important prognostic factor for this cancer is tumor stage, or extent of disease at diagnosis. Although women with low-stage tumors have a relatively good prognosis, most women diagnosed with late-stage disease eventually succumb to their cancer. In an attempt to understand early events in ovarian carcinogenesis, and to explore steps in its progression, we have applied multiple molecular genetic techniques to the analysis of 21 early-stage (stage I/II) and 17 advanced-stage (stage III/IV) ovarian tumors. These techniques included expression profiling with cDNA microarrays containing approximately 18,000 expressed sequences, and comparative genomic hybridization to address the chromosomal locations of copy number gains as well as losses. Results from the analysis indicate that early-stage ovarian cancers exhibit profound alterations in gene expression, many of which are similar to those identified in late-stage tumors. However, differences observed at the genomic level suggest differences between the early- and late-stage tumors and provide support for a progression model for ovarian cancer development.
Collapse
Affiliation(s)
- V Shridhar
- Department of Experimental Pathology, Division of Laboratory Medicine, The Mayo Clinic and Foundation, 200 First Street SW, Rochester, Minnesota 55905, USA
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
21
|
Cotler SJ, McNutt R, Patil R, Banaad-Omiotek G, Morrissey M, Abrams R, Cotler S, Jensen DM. Adult living donor liver transplantation: Preferences about donation outside the medical community. Liver Transpl 2001; 7:335-40. [PMID: 11303293 DOI: 10.1053/jlts.2001.22755] [Citation(s) in RCA: 54] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
Abstract
An increasing number of transplant centers are performing adult living donor liver transplantation (LDLT). We evaluated peoples' perspectives on possible outcomes of living donation, thresholds for donating, and views regarding the donation process. One hundred fifty people were surveyed; half were from a medical care group serving an indigent population and half were from a private clinic. Preferences about outcomes of adult living donation were ranked and quantified on a visual analogue scale. Thresholds for donation to a loved one were quantified. Sixty percent of the respondents suggested they would prefer to donate and die and have the transplant recipient live rather than forego donation and have the potential transplant recipient die of liver failure. Participants' stated threshold for living donation was a median survival for themselves of only 79%. They would require that their loved one have a median survival of 55% with transplantation before they would agree to donate. Respondents from the medical care group reported higher survival thresholds for themselves and the transplant recipient, and race was the most statistically significant predictor of those thresholds. Sex was more predictive of threshold probabilities from the private clinic. Eighty-one percent of the respondents believed that the potential donor, not a physician, should have the final say regarding candidacy for living donation. In conclusion, the findings of this survey support the use of adult LDLT. Most respondents were willing to accept mortality rates that far exceed the estimated risk of donation and favored outcomes in which a loved one was saved.
Collapse
Affiliation(s)
- S J Cotler
- Department of Medicine, Rush-Presbyterian-St Luke's Medical Center, Chicago, USA.
| | | | | | | | | | | | | | | |
Collapse
|
22
|
Abstract
BACKGROUND The purpose of this project was to develop the M. D. Anderson Symptom Inventory (MDASI), a brief measure of the severity and impact of cancer-related symptoms. METHODS A list of symptoms was generated from symptom inventories and by panels of clinicians. Twenty-six symptoms and 6 interference items were rated by a validation sample of 527 outpatients, a sample of 30 inpatients from the blood and bone marrow transplantation service, and a cross-validation sample of 113 outpatients. Clinical judgment and statistical techniques were used to reduce the number of symptoms. Reliability, validity, and sensitivity of the MDASI were examined. RESULTS Cluster analysis, best subset analysis, and clinical judgment reduced the number of symptoms to a "core" list of 13 that accounted for 64% of the variance in symptom distress. Factor analysis demonstrated a similar pattern in both outpatient samples, and two symptom factors and the interference scale were reliable. Expected differences in symptom pattern and severity were found between patients with "good" versus "poor" performance status and between patients in active therapy and patients who were seen for follow-up. Patients rated fatigue-related symptoms as the most severe. Groups of patients classified by disease or treatment had severe symptoms that were not on the "core" list. CONCLUSIONS The core items of the MDASI accounted for the majority of symptom distress reported by cancer patients in active treatment and those who were followed after treatment. The MDASI should prove useful for symptom surveys, clinical trials, and patient monitoring, and its format should allow Internet or telephone administration.
Collapse
Affiliation(s)
- C S Cleeland
- Pain Research Group, Division of Anesthesiology and Critical Care, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, USA.
| | | | | | | | | | | | | |
Collapse
|
23
|
Abstract
BACKGROUND The purpose of this project was to develop the M. D. Anderson Symptom Inventory (MDASI), a brief measure of the severity and impact of cancer-related symptoms. METHODS A list of symptoms was generated from symptom inventories and by panels of clinicians. Twenty-six symptoms and 6 interference items were rated by a validation sample of 527 outpatients, a sample of 30 inpatients from the blood and bone marrow transplantation service, and a cross-validation sample of 113 outpatients. Clinical judgment and statistical techniques were used to reduce the number of symptoms. Reliability, validity, and sensitivity of the MDASI were examined. RESULTS Cluster analysis, best subset analysis, and clinical judgment reduced the number of symptoms to a "core" list of 13 that accounted for 64% of the variance in symptom distress. Factor analysis demonstrated a similar pattern in both outpatient samples, and two symptom factors and the interference scale were reliable. Expected differences in symptom pattern and severity were found between patients with "good" versus "poor" performance status and between patients in active therapy and patients who were seen for follow-up. Patients rated fatigue-related symptoms as the most severe. Groups of patients classified by disease or treatment had severe symptoms that were not on the "core" list. CONCLUSIONS The core items of the MDASI accounted for the majority of symptom distress reported by cancer patients in active treatment and those who were followed after treatment. The MDASI should prove useful for symptom surveys, clinical trials, and patient monitoring, and its format should allow Internet or telephone administration.
Collapse
Affiliation(s)
- C S Cleeland
- Pain Research Group, Division of Anesthesiology and Critical Care, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, USA.
| | | | | | | | | | | | | |
Collapse
|
24
|
Agah A, Montalto MC, Kiesecker CL, Morrissey M, Grover M, Whoolery KL, Rother RP, Stahl GL. Isolation, characterization, and cloning of porcine complement component C7. J Immunol 2000; 165:1059-65. [PMID: 10878384 DOI: 10.4049/jimmunol.165.2.1059] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
Abstract
Activation of the complement system through the classical, alternative, or lectin pathway results in the formation of the terminal complement complex. C7 plays an integral role in the assembly of this complex with target cell membranes. To date, only human C7 has been cloned and characterized; thus, in this study, we characterized the porcine complement component C7. Porcine C7 was isolated by affinity chromatography as a single glycoprotein with an approximate molecular mass of 90 kDa and 100 kDa under reducing and nonreducing conditions, respectively. The full-length porcine C7 cDNA was isolated, and the predicted amino acid sequence exhibited 80% identity with human C7 with conservation of the cysteine backbone and two putative N-linked glycosylation sites. Porcine C7 mRNA expression was detected in all tissues investigated, except polymorphonuclear and mononuclear leukocytes. Addition of purified porcine C7 restored the hemolytic activity of C7-depleted human sera in a dose-dependent manner. A functionally inhibitory mAb against porcine C7 attenuated the hemolytic activity of human, rabbit, or rat sera, suggesting an important conserved C7 epitope among species. These data demonstrate that porcine and human C7 are highly conserved, sharing structural and functional characteristics.
Collapse
Affiliation(s)
- A Agah
- Center for Experimental Therapeutics and Reperfusion Injury, Department of Anesthesiology, Perioperative and Pain Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA
| | | | | | | | | | | | | | | |
Collapse
|
25
|
Abstract
OBJECTIVE To measure "on" freezing during unassisted walking (UW) and test if two devices, a modified inverted stick (MIS) and a visual laser beam stick (LBS) improved walking speed and number of "on" freezing episodes in patients with Parkinson's disease (PD). BACKGROUND Multiple visual cues can overcome "off' freezing episodes and can be useful in improving gait function in parkinsonian patients. These devices have not been specifically tested in "on" freezing, which is unresponsive to pharmacologic manipulations. METHODS Patients with PD, motor fluctuations and freezing while "on," attempted walking on a 60-ft track with each of three walking conditions in a randomized order: UW, MIS, and LBS. Total time to complete a trial, number of freezes, and the ratio of walking time to the number of freezes were compared using Friedman's test. RESULTS Twenty-eight patients with PD, mean age 67.81 years (standard deviation [SD] 7.54), mean disease duration 13.04 years (SD 7.49), and mean motor Unified Parkinson's Disease Rating Scale score "on" 32.59 (SD 10.93), participated in the study. There was a statistically significant correlation of time needed to complete a trial and number of freezes for all three conditions (Spearman correlations: UW 0.973, LBS 0.0.930, and MIS 0.842). The median number of freezes, median time to walk in each condition, and median walking time per freeze were not significantly different in pairwise comparisons of the three conditions (Friedman's test). Of the 28 subjects, six showed improvement with the MIS and six with the LBS in at least one outcome measure. CONCLUSION Assisting devices, specifically based on visual cues, are not consistently beneficial in overcoming "on" freezing in most patients with PD. Because this is an otherwise untreatable clinical problem and because occasional subjects do respond, cautious trials of such devices under the supervision of a health professional should be conducted to identify those patients who might benefit from their long-term use.
Collapse
Affiliation(s)
- K Kompoliti
- Department of Neurology, Rush-Presbyterian-St. Luke's Medical Center, Chicago, Illinois 60612, USA
| | | | | | | | | |
Collapse
|
26
|
Morrissey M. Mental health. Fellow feelings. Nurs Times 1999; 95:38-9. [PMID: 10455755] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/13/2023]
Affiliation(s)
- M Morrissey
- Canterbury Christ Church University College, Kent
| |
Collapse
|
27
|
Walsh BW, Spiegelman D, Morrissey M, Sacks FM. Relationship between serum estradiol levels and the increases in high-density lipoprotein levels in postmenopausal women treated with oral estradiol. J Clin Endocrinol Metab 1999; 84:985-9. [PMID: 10084583 DOI: 10.1210/jcem.84.3.5571] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
Abstract
Postmenopausal women are prescribed a standard dose of estrogen, which is optimal for a population but not for all individuals. We wished to identify if an individual's estradiol level can indicate the minimum effective dose of estrogen which maximally increases high-density lipoprotein (HDL) levels, which could be cardioprotective. We performed a prospective, double-blind crossover study in 19 healthy postmenopausal women, receiving three treatments in random order for 9 weeks each: a) placebo, b) 1 mg oral estradiol daily, and c) 2 mg oral estradiol daily. Lipoprotein and estradiol (E2) levels were measured 10-12 h after pills were taken. E2 levels with 1 mg estradiol were positively correlated with the increases in HDL levels (r = 0.70, P < 0.01). Only the eight subjects who had E2 levels < 50 pg/mL after 1 mg estradiol treatment demonstrated further increases in HDL levels by increasing the daily dose to 2 mg (by 3 +/- 5% with 1 mg estradiol and by 13 +/- 7% with 2 mg). The other 11 subjects who had E2 levels > 50 pg/mL with 1 mg estradiol had no additional benefit from increasing the estradiol dose (HDL increased by 13 +/- 9% with 1 mg, and by 17 +/- 10% with 2 mg). Thus, measurement of an E2 level the morning after taking 1 mg estradiol at bedtime identifies who may benefit from improvement in HDL levels by increasing to a 2-mg dose.
Collapse
Affiliation(s)
- B W Walsh
- Department of Obstetrics and Gynecology, Brigham and Women's Hospital, Boston, Massachusetts 02115, USA.
| | | | | | | |
Collapse
|
28
|
Abstract
BACKGROUND Fatigue is a major disease and treatment burden for cancer patients. Several scales have been created to measure fatigue, but many are long and difficult for very ill patients to complete, or they are not easy to translate for non-English speaking patients. The Brief Fatigue Inventory was developed for the rapid assessment of fatigue severity for use in both clinical screening and clinical trials. METHODS The study enrolled 305 consecutive, consenting adult inpatients and outpatients with cancer who could understand and complete the self-report measures used in the study. The same instruments also were administered to 290 community-dwelling adults to obtain a comparison sample. Research staff completed a form that indicated the primary site and stage of the cancer, rated the Eastern Cooperative Oncology Group performance status of the patient, described the characteristics of the pain, and described the current pain treatment being provided to the patients. RESULTS The BFI was shown to be an internally stable (reliable) measure that tapped a single dimension, best interpreted as severity of fatigue. It correlated highly with similar fatigue measures. Greater than 98% of patients were able to complete it. A range of scores defining severe fatigue was identified. CONCLUSIONS The BFI is a reliable instrument that allows for the rapid assessment of fatigue level in cancer patients and identifies those patients with severe fatigue.
Collapse
Affiliation(s)
- T R Mendoza
- Pain Research Group, The University of Texas M. D. Anderson Cancer Center, Houston, USA
| | | | | | | | | | | | | |
Collapse
|
29
|
Morrissey M, Rivers I. Applying the Mims-Swenson sexual health model to nurse education: offering an alternative focus on sexuality and health care. Nurse Educ Today 1998; 18:488-495. [PMID: 9847742 DOI: 10.1016/s0260-6917(98)80175-5] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/22/2023]
Abstract
Several recent publications have documented the existence of negative attitudes towards lesbians, gay men and bisexual men and women among health care professionals. It has been demonstrated that these negative attitudes predate the advent of HIV/AIDS, and are ingrained in medical and nursing education. Research has shown that, within the hospital environment, negative attitudes towards homosexuality may be directly translated into the medical and nursing care provided for lesbian, gay and bisexual clients. In this article, studies focusing on the attitudes of health care professionals towards homosexuality and bisexuality are examined, and their implications are discussed with reference to the future of nursing education.
Collapse
|
30
|
Abstract
In this article, the authors examine the possible benefits of Snoezelen for older clients. The authors suggest that nurses can be instrumental in developing and creating innovative therapeutic environments for this vulnerable client group.
Collapse
|
31
|
Abstract
Many health-care workers have a negative attitude towards their lesbian, gay and bisexual clients. Negative attitudes regarding same-sex attractions appear to be deeply ingrained in the majority of nurses' minds as a result of the socialization process. It is vital that nursing embraces issues related to sexual orientation so that quality health care can be provided for all. Doctors also have a responsibility to address the issue of homophobia both within their profession and in relation to their clients. To facilitate this, a framework using a sexual health model should be employed as this would encourage the clinician to contemplate these sensitive issues. This article will explore the attitudes of nurses and will outline the implications for care and education.
Collapse
Affiliation(s)
- M Morrissey
- Homerton School of Health Studies, Peterborough District Hospital
| |
Collapse
|
32
|
Raychaudhuri A, Kotyuk B, Pellas TC, Pastor G, Fryer LR, Morrissey M, Main AJ. Effect of CGS 25019C and other LTB4 antagonists in the mouse ear edema and rat neutropenia models. Inflamm Res 1995; 44 Suppl 2:S141-2. [PMID: 8548368 DOI: 10.1007/bf01778302] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/31/2023] Open
Affiliation(s)
- A Raychaudhuri
- Research Department, Ciba-Geigy Corp., Summit, NJ 07901-1330, USA
| | | | | | | | | | | | | |
Collapse
|
33
|
Barrett EC, Adler RF, Arpe K, Bauer P, Berg W, Chang A, Ferraro R, Ferriday J, Goodman S, Hong Y, Janowiak J, Kidd C, Kniveton D, Morrissey M, Olson W, Petty G, Rudolf B, Shibata A, Smith E, Spencer R. The first WetNet precipitation intercomparison project (PIP‐1): Interpretation of results. ACTA ACUST UNITED AC 1994. [DOI: 10.1080/02757259409532268] [Citation(s) in RCA: 24] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
|
34
|
Morrissey M, Shafer MA, Hauschild H, Reiss M, Rudolf B, Reuth W, Schneider U. Surface data sets used in WetNet's PIP‐1 from the Comprehensive Pacific Rainfall Data Base and the Global Precipitation Climatology Centre. ACTA ACUST UNITED AC 1994. [DOI: 10.1080/02757259409532259] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
|
35
|
Abstract
The findings of 247 pediatric patients who presented with supradiaphragmatic Hodgkin's disease and underwent staging laparotomies between April 1969 and December 1991 were reviewed to assess the importance of the staging laparotomy in pediatric Hodgkin's disease. A change in stage occurred in 25% of the cases reviewed. Fifty of the 202 (25%) clinical stage (CS) I or II patients were upstaged to pathological stage (PS) III or IV, and 12 of the 45 (27%) clinical stage III or IV patients were downstaged to pathological stage I or II. Possible risk factors for positive surgical staging, including gender, age, presence or absence of B symptoms, extent of involvement above the diaphragm, and histological type, were used to define subgroups of patients. Three statistically significant subgroups of patients with less than a 10% chance of restaging were identified. These groups included CS I and II patients with lymphocyte-predominant histology, CS I females, and CS III and IV females with nonlymphocyte predominant histology. These subgroups represent 24% of the cohort. Because CS is an accurate predictor of PS in these groups, treatment could be based solely on CS. The impact of radiographic imaging techniques on correctly predicting pathological stage was assessed. The rates of restaging for individuals with lymphangiography or computed axial tomography were not statistically different from those of patients without these radiographic studies. Therefore, abdominal imaging is not a substitute for surgical staging. No mortality and 2.8% morbidity occurred from staging laparotomy. Postsplenectomy sepsis and small bowel obstruction were the most common complications. Ninety-six percent of upstaged patients had splenic involvement, and 54% had positive nodal involvement.(ABSTRACT TRUNCATED AT 250 WORDS)
Collapse
Affiliation(s)
- C K Breuer
- Department of Surgery, Children's Hospital, Boston, MA 02115
| | | | | | | | | | | | | |
Collapse
|
36
|
Orlander PR, Goff DC, Morrissey M, Ramsey DJ, Wear ML, Labarthe DR, Nichaman MZ. The relation of diabetes to the severity of acute myocardial infarction and post-myocardial infarction survival in Mexican-Americans and non-Hispanic whites. The Corpus Christi Heart Project. Diabetes 1994; 43:897-902. [PMID: 8013754 DOI: 10.2337/diab.43.7.897] [Citation(s) in RCA: 58] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/28/2023]
Abstract
The effect of diabetes on survival after myocardial infarction (MI) was examined in a prospective population-based study of individuals hospitalized with MI in a bi-ethnic community of Mexican-Americans and non-Hispanic whites. Among Mexican-Americans, 54% (331 of 610) had diabetes compared with 33% (192 of 589) of non-Hispanic whites (P < 0.001). Among those with diabetes, the prevalence of a history of a cardiac event before the index admission was significantly higher (odds ratio = 1.4, 95% confidence interval [CI] 1.1-1.8) than among nondiabetic subjects. During the index hospitalization, diabetic subjects received cardiac catheterization less frequently than did nondiabetic subjects (45.1 vs. 51.5%, P = 0.03). Diabetic subjects had lower estimated ejection fractions, and the number of coronary arteries with significant obstruction (> 75%) was higher (P < 0.001). The peak creatine phosphokinase and creatine phosphokinase myocardial isoenzyme (CK-MB) levels were similar in diabetic and nondiabetic subjects. Despite a similar infarct size, diabetic subjects had a higher incidence of congestive heart failure (relative ratio = 2.2, 95% CI 1.7-2.8), more adverse indexes of short-term and long-term prognosis, and a longer average hospital stay (12.1 vs. 8.9 days, P < 0.01). After adjustment for age, sex, and ethnicity, the cumulative risk for total mortality, over 44 months of follow-up, was 37.4% among diabetic compared with 23.3% among nondiabetic subjects (P < 0.001). Diabetic subjects had a higher 28-day case-fatality rate post-MI as well as higher long-term mortality.(ABSTRACT TRUNCATED AT 250 WORDS)
Collapse
Affiliation(s)
- P R Orlander
- Department of Medicine, University of Texas Medical School at Houston 77030
| | | | | | | | | | | | | |
Collapse
|
37
|
Affiliation(s)
- M P Merchut
- Department of Neurology, Loyola University Medical Center, Maywood, IL 60153
| | | | | |
Collapse
|
38
|
Morrissey M, Leonard BE. A survey of final year medical students at University College, Galway. Ir Med J 1993; 86:154-5. [PMID: 8225919] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/29/2023]
Abstract
The results of this survey of final year medical students at a provincial Irish university showed that over three-quarters came from families in which at least one parent was in a professional or semi-professional occupation. The majority of the students had repeated their Leaving Certificate examination. Most students expressed dissatisfaction with the career guidance counselling they received during their second level education. All the students came from secondary schools. While the majority expressed satisfaction with their choice of University course, approximately one-third had considered withdrawing from the course, particularly during the pre-clinical years. The main reasons given were financial difficulties, personal problems and difficulties with the course. Despite the provision of student counsellors and academic staff members to assist such students, the majority did not consult any staff member for help. Most students expected they would have to obtain employment outside of Ireland.
Collapse
Affiliation(s)
- M Morrissey
- Dept of Pharmacology, University College, Galway
| | | |
Collapse
|
39
|
Affiliation(s)
- A J Lopez
- Loyola University Medical Center, Maywood, Illinois
| | | | | | | |
Collapse
|
40
|
Abstract
"Twenty-five Caribbean and Latin American nations were examined to determine the relationship between potential female headed families and other social indicators. Regression analysis reveals that women's labor market participation is associated with the proportion of families potentially headed by women. The share of girls in secondary school is also associated with the dependent variable. Social indicators of modernization and dependency were regressed on potential female-headed households. Neither approach alone explains the formation of female-headed families in the region."
Collapse
|
41
|
Wells R, Morrissey M, Hughson R. Internal work and physiological responses during concentric and eccentric cycle ergometry. Eur J Appl Physiol Occup Physiol 1986; 55:295-301. [PMID: 3732256 DOI: 10.1007/bf02343802] [Citation(s) in RCA: 50] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/07/2023]
Abstract
Internal mechanical work during cycling, required to raise and lower the legs and change their velocities, is shown to be an important factor when interpreting physiological responses to cycle ergometer exercise. The internal work required to move the legs during concentric and eccentric cycle ergometry at different speeds and workloads was calculated from segmental energy changes determined using cinematography and directly using an eccentric ergometer. The mean internal work rates obtained at pedal frequencies of 30, 60 and 90 min-1 were 11.5, 20 and 62 W respectively. When these estimates were added to the external work rates, they increased concentric and decreased eccentric work rates. The largest differences were seen at low work rates and high pedal frequencies during which concentric work rates increased by 51% and eccentric decreased 60% by the inclusion of internal work. When comparisons of concentric and eccentric cycling at equal uncorrected work rates were made, neglecting to include internal work introduced errors ranging from 12 to 97%. The calculated estimates of internal work agreed well with the power supplied by the eccentric ergometer to move the legs passively. The investigations show that the inclusion of internal work is important when comparing physiological responses during concentric and eccentric ergometry, especially when pedal frequencies exceed 60 min-1 and when work rates are small.
Collapse
|
42
|
Morrissey M. Hysterectomy: postoperative exercise. Med J Aust 1985; 142:663. [PMID: 4000051 DOI: 10.5694/j.1326-5377.1985.tb113577.x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/08/2023]
|
43
|
Kineiko RW, Floering DA, Morrissey M. Laboratory evaluation of the Boehringer Mannheim "Hitachi 705" automatic analyzer. Clin Chem 1983; 29:688-91. [PMID: 6831699] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/22/2023]
Abstract
We evaluated a new multi-channel chemistry analyzer, the Hitachi 705 Automatic Analyzer, marketed by Boehringer Mannheim Diagnostics, Inc. The instrument is a computer-controlled discrete analyzer, which can be run in a combination profile mode and single-test mode. Sixteen different tests per sample may be performed at the rate of 180 tests per hour. The Hitachi 705 is especially suitable for use in hospitals that do not perform profile testing. Precision and linearity were excellent and the instrument was relatively trouble-free, with little operator attention required during operation. The Hitachi 705 was easily interfaced to our laboratory computer. We compared the performance of the instrument with that of the Du Pont aca; the two instruments compared favorably.
Collapse
|
44
|
Abstract
Abstract
We evaluated a new multi-channel chemistry analyzer, the Hitachi 705 Automatic Analyzer, marketed by Boehringer Mannheim Diagnostics, Inc. The instrument is a computer-controlled discrete analyzer, which can be run in a combination profile mode and single-test mode. Sixteen different tests per sample may be performed at the rate of 180 tests per hour. The Hitachi 705 is especially suitable for use in hospitals that do not perform profile testing. Precision and linearity were excellent and the instrument was relatively trouble-free, with little operator attention required during operation. The Hitachi 705 was easily interfaced to our laboratory computer. We compared the performance of the instrument with that of the Du Pont aca; the two instruments compared favorably.
Collapse
|
45
|
Byrne KM, Lattanzi SM, Morrissey M. "Don't let me fall". Am J Nurs 1982; 82:1242-5. [PMID: 6921008] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/22/2023]
|
46
|
|
47
|
Hughson RL, Morrissey M. Delayed kinetics of respiratory gas exchange in the transition from prior exercise. J Appl Physiol Respir Environ Exerc Physiol 1982; 52:921-9. [PMID: 6806226 DOI: 10.1152/jappl.1982.52.4.921] [Citation(s) in RCA: 106] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/22/2023]
Abstract
The kinetics of oxygen uptake (VO2), carbon dioxide output (VCO2), and expired ventilation (VE) in the transition from rest or from prior exercise were studied in response to step increases in power output (PO). The data were modeled with a single-component exponential function incorporating a time delay (TD). Each subject exercised on four occasions. Test 1 was an incremental test for determination of ventilatory anaerobic threshold (AT). Step increase tests were rest to 80% of PO at AT (test 2), rest-40% AT (3a), 40-80% AT (3b), rest-40% AT (4a), and 40-120% AT (4b). Respiratory gas exchange was monitored by open-circuit techniques. The VO2 kinetics showed the time constant (tau) to be longer in the transitions from prior exercise [tests 3b and 4b were 60.6 +/- 10.8 (SD) and 79.2 +/- 17.4 s] than from rest (tests 2, 3a, and 4a were 37.8 +/- 7.2, 30.0 +/- 7.8, and 39.6 +/- 17.4 s). The mean response time (MRT = tau + TD) was also longer for these tests. Kinetic analysis for VCO2 showed a tendency for tau to be shorter for the tests from prior exercise, but neither tau nor tau + TD were significantly different between tests. In contrast to VCO2, VE kinetics showed a significantly longer tau + TD for test 3b (P less than 0.05) and test 4b (P less than 0.01). This study has shown the VO2 kinetics to be delayed when a given increment in PO occurred from prior exercise, whether the final PO was below or above the AT. Further, the dissociation of VCO2 and VE kinetics does not support a direct link between these two variables as the sole control factor in exercise hyperpnea.
Collapse
|
48
|
|